The present disclosure generally relates to systems, devices, and methods for treating medical conditions using an implantable device, and more particularly, to systems, devices, and methods which include or use a motion sensor to detect a patient's level of activity.
Pacing instruments can be used to treat patients suffering from various heart conditions that result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. These heart conditions may lead to rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various devices (e.g., pacemakers, defibrillators, etc.) have been implanted in a patient's body. Such devices may monitor and provide electrical stimulation to the heart to help the heart operate in a more normal, efficient and/or safe manner. In some cases, a patient may have multiple implanted devices.
Motion detectors have been used in some pacemakers and other implantable devices to obtain a measure of the activity level of the patient. For example, rate adaptive cardiac pacemakers may adjust the rate at which the patient's heart is paced up or down in response to detected motion of the patient. By so doing, the pacemaker is able to adapt to the activity level of the patient, allowing a more active lifestyle than could be achieved without rate adaptive pacing. New and alternative approaches to the use of motion sensors are desired.
In some embodiments the present invention relates to a leadless cardiac pacemaker (LCP) or other implantable cardiac device having a motion sensor for detecting motion of the patient. The standard implant for pacemakers has long been the transvenous pacemaker, having a canister housing operational circuitry typically implanted in the upper chest of the patient and a lead which traverses the vasculature to the interior of the heart, with electrodes attached to the heart to facilitate therapy delivery and cardiac signal sensing. Such devices included a motion sensor in the canister, placed outside the ribs on the patient's chest in most examples.
For certain newer generation devices including the LCP, the entire product, including the motion sensor, may be placed inside or in close proximity to the heart. However, such placement means that the motion sensor may detect motion of the heart when it beats in addition to motion caused by bodily movement of the patient. In several embodiments the present invention is directed toward methods and devices that use the temporal patterns of cardiac movement to avoid detecting cardiac motion in place of bodily motion.
This overview is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the present patent application.
In the drawings, which are not necessarily drawn to scale, like numerals may describe similar components in different views. Like numerals having different letter suffixes may represent different instances of similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
This disclosure describes systems, devices, and methods for delivering electrical stimulation to a heart in a rate adaptive manner. Healthy people's bodies generally adjust the rate at which their hearts beat in response to higher or lower metabolic needs, for example during exercise or in response to various external stimuli. However, some people develop diseases or conditions which affect their bodies' abilities to cause their hearts to contract in an effective manner. Accordingly, devices in accordance with the present disclosure may be implanted in such people. In some instances, the implanted devices may deliver electrical stimulation on an on-going basis and adjust the rate of delivered electrical stimulation in accordance with sensed physiological parameters indicative of increased metabolic needs.
More specifically,
As depicted in
Electrodes 114 may include one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, electrodes 114 may be generally disposed on either end of LCP 100 and may be in electrical communication with one or more of modules 102, 104, 106, 108, and 110. In embodiments where electrodes 114 are secured directly to housing 120, an insulating material may electrically isolate the electrodes 114 from adjacent electrodes, housing 120, and/or other parts of LCP 100. In some instances, some or all of electrodes 114 may be spaced from housing 120 and connected to housing 120 and/or other components of LCP 100 through connecting wires. In such instances, the electrodes 114 may be placed on a tail (not shown) that extends out away from the housing 120. As shown in
In the embodiment shown, communication module 102 may be electrically coupled to electrodes 114 and/or 114′ and may be configured to deliver communication pulses to tissues of the patient for communicating with other devices such as sensors, programmers, other medical devices, and/or the like. Communication signals, as used herein, may be any modulated signal that conveys information to another device, either by itself or in conjunction with one or more other modulated signals. In some embodiments, communication signals may be limited to sub-threshold signals that do not result in capture of the heart yet still convey information. The communication signals may be delivered to another device that is located either external or internal to the patient's body. In some instances, the communication may take the form of distinct communication pulses separated by various amounts of time. In some of these cases, the timing between successive pulses may convey information. Communication module 102 may additionally be configured to sense for communication signals delivered by other devices, which may be located external or internal to the patient's body.
Communication module 102 may communicate to help accomplish one or more desired functions. Some example functions include delivering sensed data, using communicated data for determining occurrences of events such as arrhythmias, coordinating delivery of electrical stimulation therapy, and/or other functions. In some cases, LCP 100 may use communication signals to communicate raw information, processed information, messages and/or commands, and/or other data. Raw information may include information such as sensed electrical signals (e.g. a sensed EGM), signals gathered from coupled sensors, and the like. In some embodiments, the processed information may include signals that have been filtered using one or more signal processing techniques. Processed information may also include parameters and/or events that are determined by the LCP 100 and/or another device, such as a determined heart rate, timing of determined heartbeats, timing of other determined events, determinations of threshold crossings, expirations of monitored time periods, activity level parameters, blood-oxygen parameters, blood pressure parameters, heart sound parameters, and the like. Messages and/or commands may include instructions or the like directing another device to take action, notifications of imminent actions of the sending device, requests for reading from the receiving device, requests for writing data to the receiving device, information messages, and/or other messages commands.
In at least some embodiments, communication module 102 (or LCP 100) may further include switching circuitry to selectively connect one or more of electrodes 114 and/or 114′ to communication module 102 in order to select which electrodes 114 and/or 114′ that communication module 102 delivers communication pulses. It is contemplated that communication module 102 may be communicating with other devices via conducted signals, radio frequency (RF) signals, optical signals, acoustic signals, inductive coupling, and/or any other suitable communication methodology. Where communication module 102 generates electrical communication signals, communication module 102 may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering communication signals. In the embodiment shown, communication module 102 may use energy stored in energy storage module 112 to generate the communication signals. In at least some examples, communication module 102 may include a switching circuit that is connected to energy storage module 112 and, with the switching circuitry, may connect energy storage module 112 to one or more of electrodes 114/114′ to generate the communication signals.
As shown in
The LCP 100 may vary the rate at which pulse generator 104 generates the electrical stimulation pulses, for example in rate adaptive pacing. These are just some examples. When used to treat other ailments, the pulse generator module 104 may generate electrical stimulation pulses suitable for neurostimulation or neuromodulation therapy or the like.
Pulse generator module 104 may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering appropriate electrical stimulation pulses. In the embodiment shown, pulse generator module 104 may use energy stored in energy storage module 112 to generate the electrical stimulation pulses. In some examples, pulse generator module 104 may include a switching circuit that is connected to energy storage module 112 and may connect energy storage module 112 to one or more of electrodes 114/114′ to generate electrical stimulation pulses.
Pulse generator module 104 may include the capability to modify the electrical stimulation pulses, such as by adjusting the pulse width and/or amplitude of the electrical stimulation pulses. When pacing the heart, this may help tailor the electrical stimulation pulses to capture the heart a particular patient, sometimes with reduced battery usage. For neurostimulation therapy, adjusting the pulse width and/or amplitude may help tailor the therapy for a particular application and/or help make the therapy more effective for a particular patient.
In some embodiments, LCP 100 may include an electrical sensing module 106 and mechanical sensing module 108. Electrical sensing module 106 may be configured to sense intrinsic cardiac electrical signals conducted from electrodes 114 and/or 114′ to electrical sensing module 106. For example, electrical sensing module 106 may be electrically connected to one or more electrodes 114 and/or 114′ and electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through electrodes 114 and/or 114′ via a sensor amplifier or the like. In some embodiments, the cardiac electrical signals may represent local information from the chamber in which LCP 100 is implanted. For instance, if LCP 100 is implanted within a ventricle of the heart, cardiac electrical signals sensed by LCP 100 through electrodes 114 and/or 114′ may represent ventricular cardiac electrical signals.
Mechanical sensing module 108 may include, or be electrically connected to, various sensors, such as accelerometers, blood pressure sensors, heart sound sensors, piezoelectric sensors, blood-oxygen sensors, and/or other sensors which measure one or more physiological parameters of the heart and/or patient. Mechanical sensing module 108 may gather signals from the sensors indicative of the various physiological parameters. Both electrical sensing module 106 and mechanical sensing module 108 may be connected to processing module 110 and may provide signals representative of the sensed cardiac electrical signals and/or physiological signals to processing module 110. Although described with respect to
The mechanical sensing module may include, for example, a micro-electro-mechanical system (MEMS) based motion sensor. This may include a 1, 2 or 3 dimensional motion sensor and may take any of numerous forms known in the art. Some examples may include a micro-machine size vibrating element that varies an electrical parameter when motion impacts it. To facilitate sensing, the motion sensor can be turned “on,” requiring current drain, and the output can then be sampled to generate an output. Keeping the motion sensor “on” all the time may drain battery sourced current unnecessarily, and so duty cycling is performed to minimize current draw in some embodiments.
Processing module 110 may be configured to direct the operation of LCP 100. For example, processing module 110 may be configured to receive cardiac electrical signals from electrical sensing module 106 and/or physiological signals from mechanical sensing module 108. Based on the received signals, processing module 110 may determine, for example, occurrences and types of arrhythmias. Processing module 110 may further receive information from communication module 102. In some embodiments, processing module 110 may additionally use such received information to determine occurrences and types of arrhythmias. However, in other embodiments, LCP 100 may use the received information instead of the signals received from electrical sensing module 106 and/or mechanical sensing module 108—for instance if the received information is deemed to be more accurate than the signals received from electrical sensing module 106 and/or mechanical sensing module 108 or if electrical sensing module 106 and/or mechanical sensing module 108 have been disabled or omitted from LCP 100.
After determining therapy is needed, processing module 110 may control pulse generator module 104 to generate electrical stimulation pulses in accordance with one or more electrical stimulation therapy regimens. For example, processing module 110 may control pulse generator module 104 to generate pacing pulses with varying parameters and in different sequences to effectuate one or more electrical stimulation therapies. As one example, in controlling pulse generator module 104 to deliver bradycardia pacing therapy, processing module 110 may control pulse generator module 104 to deliver pacing pulses designed to capture the heart of the patient at a regular interval to help prevent the heart of a patient from falling below a predetermined threshold.
In some embodiments, processing module 110 may further control communication module 102 to send information to other devices. For example, processing module 110 may control communication module 102 to generate one or more communication signals for communicating with other devices of a system of devices. For instance, processing module 110 may control communication module 102 to generate communication signals in particular pulse sequences, where the specific sequences convey different information. Communication module 102 may also receive communication signals for potential action by processing module 110.
In some embodiments, processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of LCP 100. By using a pre-programmed chip, processing module 110 may use less power than other programmable circuits while able to maintain basic functionality, thereby potentially increasing the battery life of LCP 100. In other instances, processing module 110 may include a programmable microprocessor or the like. Such a programmable microprocessor may allow a user to adjust the control logic of LCP 100 after manufacture, thereby allowing for greater flexibility of LCP 100 than when using a pre-programmed chip.
Processing module 110, in additional embodiments, may include a memory circuit and processing module 110 may store information on and read information from the memory circuit. In other embodiments, LCP 100 may include a separate memory circuit (not shown) that is in communication with processing module 110, such that processing module 110 may read and write information to and from the separate memory circuit. The memory circuit, whether part of processing module 110 or separate from processing module 110, may be volatile memory, non-volatile memory, or a combination of volatile memory and non-volatile memory.
Collectively the processing module 110, mechanical sensing module 108, electrical sensing module 106, pulse generator module 104, and communication module 102 may be referred to as the operational circuitry of the LCP. In some examples the individual modules 102, 104, 106, 108, 110 may be subcomponents on a single hybrid or circuit board, or even within a single VSLI or ASIC, or may be spread across several hybrids, circuit boards, VSLI or ASIC components. In some examples, certain elements of processing module 110 are performed in the digital domain—such as determining whether to deliver therapy and operating the communication module when awoken for such a purpose—while others are performed in the analog domain—such as ongoing monitoring of the received electrical and/or motion signal until a significant perturbation of either signal or a timeout occurs, allowing the digital circuitry to stay in a low power state by duty cycling to sleep. On whole, the operational circuitry may be configured to perform the various methods shown herein and below claimed, by reference to memory and/or by operation of application-specific circuitry and/or ASIC chips.
Energy storage module 112 may provide a power source to LCP 100 for its operations. In some embodiments, energy storage module 112 may be a non-rechargeable lithium-based battery. In other embodiments, the non-rechargeable battery may be made from other suitable materials. In some embodiments, energy storage module 112 may include a rechargeable battery. For embodiments with a rechargeable battery, there may additionally be a recharging circuit using, for example, a coil that receives an electrical or magnetic field to facilitate recharging transcutaneously, as is well known in the art. In other embodiments, biological energy capture devices may be used to take advantage of energy that can be generated using the cardiac or other biological motion. In still other embodiments, energy storage module 112 may include other types of energy storage devices such as super capacitors.
To implant LCP 100 inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix LCP 100 to the cardiac tissue of the patient's heart. To facilitate fixation, LCP 100 may include one or more anchors 116. The one or more anchors 116 are shown schematically in
In some examples, LCP 100 may be configured to be implanted on a patient's heart or within a chamber of the patient's heart. For instance, LCP 100 may be implanted within any of a left atrium, right atrium, left ventricle, coronary sinus, or right ventricle of a patient's heart. By being implanted within a specific chamber, LCP 100 may be able to sense cardiac electrical signals originating or emanating from the specific chamber that other devices may not be able to sense with such resolution. Where LCP 100 is configured to be implanted on a patient's heart, LCP 100 may be configured to be implanted on or adjacent to one of the chambers of the heart, or on or adjacent to a path along which intrinsically generated cardiac electrical signals generally follow. In these examples, LCP 100 may also have an enhanced ability to sense localized intrinsic cardiac electrical signals and deliver localized electrical stimulation therapy.
In some instances, LCP 100 may be configured to deliver rate-adaptive pacing therapy to a patient's heart. For instance, LCP 100 may be configured to deliver electrical stimulation pulses to the heart of the patient on an on-going basis to help ensure that the patient's heart contracts in a safe and effective manner. LCP 100 may additionally sense one or more signals, for example using electrical sensing module 106 and/or mechanical sensing module 108, and determine, based on the sensed one or more signals, whether to change the rate of delivery of the electrical stimulation pulses.
For example, based on the sensed one or more signals, LCP 100 may determine that there is less of a need for cardiac output, and may decrease the rate of delivery of the electrical stimulation pulses. In other instances, based on the one or more sensed signals, LCP 100 may determine that there is a need for increased cardiac output, and may increase the rate of delivery of the electrical stimulation pulses. Adjusting the rate of delivery of the electrical stimulation pulses based on the sensed one or more signals may extend the battery life of LCP 100 by only requiring higher rates of delivery of electrical stimulation pulses when the sensed one or more signals indicate there is a need for increased cardiac output. Additionally, adjusting the rate of delivery of the electrical stimulation pulses may increase a comfort level of the patient by more closely matching the rate of delivery of electrical stimulation pulses with the cardiac output need of the patient.
Where LCP 100 adjusts the rate of delivery of electrical stimulation pulses based on the sensed one or more signals, LCP 100 may in some cases determine a respiration rate based on the sensed one or more signals. Respiration rate may be indicative of a relative cardiac output need for the patient. For example, an increased respiration rate may indicate that there is a need for increased cardiac output, and a decreased respiration rate may indicate less of a need for cardiac output. Accordingly, and when so provided, LCP 100 may adjust the rate of delivery of the electrical stimulation pulses based on the determined respiration rate.
In at least some examples, LCP 100 may include a motion sensor (such as an accelerometer) and may determine a measure related to the respiration rate based on the sensed motion sensor signal. Where LCP 100 is implanted on a patient's heart or within the heart, the motion sensor signal may include signals indicative of movement related to a number of different causes. For instance, the motion sensor signal may include movement related to the gross movement of the patient, such as walking, bending, or other gross body movements. Additionally, the motion sensor signal may include movement related to the contraction of the heart, particularly when LCP 100 is implanted on or within the heart. Additionally, the motion sensor signal may include movement related to the inhalation and exhalation of the patient (i.e. respiration). For instance, as a patient breathes in and out, the lungs apply different pressure to the heart and the intrathoracic pressure changes accordingly. This change in the intrathoracic pressure may cause changes in the shape and size of the various chambers of the heart, as well as the movement of the heart and the heart chambers. After inhalation, the intrathoracic pressure may be relatively higher, which may decrease the volume of blood that flows into one or more of the chambers of the heart during a cardiac cycle. Conversely, after exhalation, the intrathoracic pressure may be relatively lower, which may allow relatively more blood to enter the chambers of the heart during a cardiac cycle. These differences in the amount of blood flowing into and out of the heart and any movement of the heart or heart chambers due to the changes in intrathoracic pressure may be contained in the motion sensor signal.
A motion sensor may be used to measure inotropic changes in the myocardium; either positive or negative changes. Patients having chronotropic incompetence can still have appropriate contractility responses to increased metabolic demand. For example with increased metabolic demand, contractility increases due to adrenergic excitation. The opposite occurs with decreased metabolic demand.
Although an LCP serves as the platform for much of the below description and above detail, any implantable device having a motion sensor may take advantage of the presently described enhancements. Other devices may include drug or other substance delivery systems, neurostimulator or neuromodulation systems, and implantable cardiac monitoring systems, for example.
At 204, the ventricular pressure is represented, with a peak at 222 as the cardiac volume decreases (shown by line 202). Atrial pressure is represented at 206. The atrial pressure 206 illustrates changes that are much smaller than those of the ventricles.
The phonocardiogram is shown at 208, with the first heart sound at 210, over the QRS complex during systole, the second heart sound 212 representing the end of systole and start of diastole, and the third heart sound 214 occurring still later. The first heart sound 210 corresponds to closing of the atrioventricular valves, that is, the tricuspid and mitral valves. The second heart sounds 212 correspond to closure of the aortic and pulmonary valves. The third heart sound 214 is generally less common and of lower amplitude than the first two heart sounds 210, 212 and may relate, it is thought, to blood filling the ventricles. The motion and sounds represented by the changing ventricular volume 202 and heart sounds 210, 212, 214 can all create interference for a motion sensor, which may be sensitive to each of these.
The inventors have recognized that a useful goal in this context is to identify a relatively quiet period of time, illustrated at 230, during which cardiac-sourced interference is reduced. Although the third heart sound 214 may overlap this period 230, it should be noted that the third heart sound 214 is not universally observed and is the lowest amplitude of the heart sounds and so is less likely to cause significant interference. The inventors have recognized that an LCP may be configured for temporal avoidance of cardiac motion interference, enhancing the signal for analysis and potentially avoiding or reducing computational burden associated with other filtering techniques.
x[i], x[i+1], x[i+2], x[i+3]
y[i], y[i+1], y[i+2], y[i+3]
z[i], z[i+1], z[i+2], z[i+3]
The math is not so simple as a single number coming out. Computational burdens are presented by such math in an implanted system.
Sampling may be called on a constant basis; historically accelerometer or motion sensor outputs in implantable medical systems would be sampled at rates of 10 to 50 hertz. However, in examples further shown below, sampling occurs in response to detected heart beats identified by analyzing the cardiac electrical signal. For example, the cardiac electrical signal (sometimes referred to as the cardiac electrogram, if captured from within the heart, or electrocardiogram, if captured outside the heart) may be compared to a time-varying threshold to identify the R-wave or QRS complex representative of an individual cardiac cycle. If desired, as alternatives, heart sounds or blood pressure measurements may instead be used to identify a cardiac cycle. As discussed further below, when taking one or more samples with each cardiac cycle, timing of the samples is be selected, in some examples, to avoid certain noise sources.
In the example of
The output of the integral 304 is averaged over a long interval at 306 to yield a baseline. At 308, the instantaneous output from block 304 is compared by subtraction to the long interval average from block 306. The difference may be multiplied in a gain stage at 310 and fed into a moving average block 312, to allow smoothing of the motion sensor signal. For example, a patient rolling over in his or her sleep could be detected as significant motion by such a system, but the moving average block 312 would smooth this large motion over a period of in the range of 5 to 30 seconds. Such smoothing would avoid inappropriate rate response to isolated motion.
For simplicity, several examples herein refer a difference being calculated. In some examples, a difference is calculated relative to a baseline by subtraction. In other example, a difference may be a ratio of a measured value to a baseline value, that is, if the baseline is represented by a non-zero measurement output, the difference may be the ratio to the non-zero output. The word difference is intended to cover all such permutations of a comparison to baseline to determine a difference.
The moving average 312 may then be compared at 316 to a rate response level 314 representing the current state of rate response. For example, if the current state is at a base pacing level—that is, no rate response, then the level 314 may be zero, and an increase would be identified if the moving average is greater than level 314. The output 318, which is the temporary response level, is used to modify the existing state.
In some examples, the various blocks shown in
The output sample is may go through computation and filtering 408 (such as amplifying, root-mean-square assessment, smoothing, etc.) and an average signal within the sample may then be calculated at 410. The pre-processing at blocks 408, 410 may be on a per-sample basis, or may be performed for all samples (if multiple are taken) within a cardiac cycle, if desired. The pre-processed sample can be compared to a long term average 412 in block 414, processed further with an optional gain stage 416, and smoothed to generate a moving average at 418. As with
In a further example, the trigger 402 may be either a detected cardiac event, if one occurs, or pace delivery if the bradycardia pacing escape threshold is exceeded. In such a design, the first delay 402 may be configured for intrinsic (non-paced) cardiac cycles, and the second delay 404 may be configured for paced cardiac cycles. This accounts for the differences between intrinsic and paced cardiac cycles since, for example, the paced cycles may have different conduction characteristics and wider QRS complexes than intrinsic beats.
Again, the sample 500 is pre-processed at 508 using, for example, a sum of square approach or the like, and one or more peak motion detection from the interval are identified at 510. For example, it may be desirable to take a comprehensive view of the cardiac motion artifact by sampling at a number of times within a cardiac cycle to then identify peaks and generate a histogram 512. Rank valuation can then be performed at 514, and one or more peaks passed through to the gain and integration stages 516, 520. A decay value may be incorporated as well from block 518 with the decay representing expected value within a cycle. These outputs may be used to compare to the existing state 522 in a comparison at 524 to yield an adjustment calculation 526. In other examples the method may stop with the histogram at 512 which may be useful to monitor, for example, the stages (strength or duration, for example) of cardiac contraction.
Alignments for one or more states, including an active state, or, alternatively, a sleep state, can be stored at 606 for use in the comparison at 608. A match threshold is applied at 610 to determine whether there is a match to an active or sleep state. If an active state is identified or cannot be eliminated, then the active motion sensor tracking mode may be set at 612. Otherwise, a passive motion sensor tracking mode is set and kept in place for a delay period, as indicated at 614, and the motion sensor subcomponents of the implantable medical device are put to sleep at 616 until the delay period expires. Illustrative delay periods may range from a minute to an hour. In one example, if the patient appears to be asleep or inactive, a thirty-minute delay is set to conserve energy.
A sleep function as shown in
The motion sensor data and second signal data are aligned and correlated at 704, and used to generate a configuration for the motion sensor data 706. For example, the aligning and correlating step may be performed to facilitate identifying a quiet time 720 in the motion sensor data relative to alignment or reference points in the second signal data 702.
To further facilitate the configuration, patient activity 710 and/or the status of pacing therapy 712 can be controlled. For example, the data collection 700, 702 is performed, in one illustration, while the patient is told to remain at rest, thus controlling patient activity 710. In this state, the motion sensor should only identify motion caused by cardiac motion and/or sounds within the heart—since an accelerometer-based motion sensor may be sensitive to vibrations (“sounds”) occurring in the heart. Thus a quiet phase of the motion sensor output would provide a good baseline for identifying patient activity. The process may be repeated with pacing on and off, as indicated at 712, to ensure that quiet times 720 can be identified in either circumstance. Moreover, if the quiet time shifts based on whether pacing is on or off, the configuration 706 would be adjusted to ensure the right quiet time is selected for both paced and non-paced beats.
It is envisioned that a system will operate in a learning mode—that is, the system may not necessarily rely on specific landmarks or theoretical bases when selecting a quiet time. However, in reality, it is expected that devices will choose a time period as indicated by
Alternatively, sampling, with or without delays may be triggered by a different detectable event. For example, the configuration 706 may store a time period from the T-wave or end of the T-wave. The configuration 706 may instead be reflected in identification of a quiescent state of the electrocardiogram where the ECG or EGM is electrically at baseline for a period of time, as such a state would correspond to the period between the T-wave and the P-wave.
For those patients who exhibit a detectable third heart sound, the configuration 706 may be selected to ensure motion sensor sampling before or after the third heart sound in order to avoid it. Such a result may occur from the device learning when a quiet time takes place relative to one or more cardiac signals, or it may be ensured using inputs from a physician.
In some examples a further set of manipulations of the state of the patient may be had. Configuration may be performed while the patient is in a state of rest as well as during patient activity selected to increase the heart rate. In conjunction with the patient activity the output pacing rate may be increased by the implantable device, if needed. For example, a baseline configuration may be used during a learning period and, once data capturing and correlation steps are completed, a tailored configuration can be stored for the patient. By rechecking the configuration at increased heart rates, the appropriate timing of the quiet time at various heart rates can be determined and stored as part of the configuration 706.
In one example, the pacing rate may be increased to confirm the mechanical quiet phase remains quiet at increased rates (or, if the timing of the quiet phase moves, to allow for adjustment). That is, if the quiet time at low rates is no longer quiet at high rates due to motion intrinsic to the heart, the configuration of the quiet time can be adjusted. The quiet time may be preferably selected to avoid inappropriate feedback from the heart itself, which could perpetuate an unnecessarily high cardiac rate if not avoided.
Much of the above presumes a ventricular placement of the implantable device. If an implantable device is placed in the atrium, it may be more suitable to use the P-wave as a trigger point, since it will be the larger signal to the atrial device absent cross-chamber noise. In this instance, the implantable device is more likely to identify a quiet time that may occur during systole, that is, while the ventricles are ejecting blood to the rest of the body.
Within
The delay 802 may be defined or determined in a number of ways. In some examples, a learning process is used at 820, such as the process of
Further to the example of
Once a baseline is established at 1002, a sample is taken at 1004. The sample 1004 is then compared to the baseline at 1006, to generate a difference that is used to assess patient activity at 1008. If desired, several samples may be taken and averaged together, or a smoothing function may be applied to a series of samples prior to comparing to the baseline 1006.
Next, data capture is performed at 1102. Data capture may include capturing data from a motion sensor as well as a second data input or sensor such as the electrogram. Capture of the motion sensor output and second signal may be continuous 1120 or at high rate 1122 for the purposes of configuration, with the intent being that once configuration is completed a lower rate may be implemented.
Steps 1100 and 1102 may be repeated as shown at 1104 with new instructions to the patient for second and subsequent iterations. Once data is captured, the method determines a quiet time in the motion sensor signal using a trigger or reference point identified in the second signal data. The analysis of this type may be performed by the implanted device 1130 or may be performed by an external device in communication with an implanted device 1132.
It is not necessary to have multiple implanted devices, but it is envisioned that at least some patients will have multiple devices. In some examples, one or both implanted device 1204, 1206 has a motion sensor. In some examples, the motion sensor of one of the devices is disabled after configuration has been performed, if it can be determined that performance of one or the other is better or worse and the devices operate in coordination with one another. In some examples, an atrial device 1206 may be of smaller size and lesser mass, and omits a motion sensor which is instead provided in the ventricular device 1204.
Alternatively, the devices may be identical and whichever device has a greater available battery capacity is used for motion capture, while the other device renders a motion sensor inactive. For example, it may be that the atrial device 1206 is anticipated to use less power in therapy delivery than the ventricular device 1204, such that motion sensing is performed with just the atrial device 1206.
In some examples, the two separate devices 1204 and 1206 may provide synchronized motion capture to identify an appropriate configuration. For example, both devices 1204 and 1206 may communicate captured motion data out to the external programmer 1210, where the motion sensing data is captured in overlapping time periods. Motion that is sensed due to patient movement should be identified in both of the devices, while local motion from cardiac chamber movement, for example, would not necessarily show up in each device's motion sensor output. By comparing the signals, the bodily motion signal can be extracted. Next, working backwards, it would be determined which time periods in one or both implanted devise 1204 and 1206 is capturing the bodily motion accurately and without interference from local cardiac motion. A configuration would be identified and stored for one or both implanted devices 1204 and 1206.
A first non-limiting example is an implantable device (ID) comprising a power source, operational circuitry, a motion sensor, and electrodes, the electrodes configured to capture a cardiac electrical signal, wherein the operational circuitry comprises: trigger means for determining that a predefined event has occurred in the heart of the patient using a signal from the electrodes; sampling means for sampling an output of the motion sensor in response to the trigger means. Illustrative examples of a trigger means includes a circuit (such as a comparator) or software implemented instruction for comparing a representation (analog or digital) of a received cardiac signal to a predetermined threshold such as a threshold as described in U.S. Pat. No. 8,565,878, the disclosure of which is incorporated herein by reference. Such triggers are also described above. Illustrative examples of sampling means include any suitable sampling circuit such as a capacitive sample and hold circuit in which, for example, an output is switched to a capacitor, charging the capacitor up or down to a level related to the sampled signal, and a comparator is used to drive a second capacitor to match the sampling capacitor, or a comparator circuit, and an analog-to-digital convertor capable of retaining or passing to memory an output of a measurement, among others. The drawings indicate certain examples including trigger 402 and sampling 400 in
A second non-limiting example is the ID of the first non-limiting example, wherein the sampling means further comprises delay means for waiting a delay period following activation of the trigger means before sampling the output of the motion sensor. Illustrative delay means may include a timer and associated memory or comparator for setting the duration to run the timer, or may include a capacitor that can be charged to a selected level and then discharged in predictable fashion. Delay is illustrated in the Figures, for example, at
A third non-limiting example is an ID as in the second non-limiting example, wherein the motion sensor is configured to operate in a low-power mode except to facilitate the sampling means taking a sample of the output thereof. A fourth non-limiting example is an ID as in either of the second or third non-limiting examples, wherein the predefined event is one of an R-wave, a pacing impulse, or a QRS complex, and the delay period is selected to expire prior to occurrence of a P-wave. A fifth non-limiting example is an ID as in any of the second to fourth non-limiting examples further comprising a spurious event detector configured to determine whether an event occurs during or after the delay period and, if so, the spurious event detector is configured to interrupt the sampling means or cause the sampling means to discard the sampled output of the motion sensor. A sixth non-limiting example is an ID as in the fifth non-limiting example, wherein the specified cardiac event is a ventricular contraction.
A seventh non-limiting example is an ID as in any of the second to sixth non-limiting examples, wherein the operational circuitry includes means for initializing the ID including: collection means to collect a set of data points from the motion sensor and from a cardiac electrical signal from the electrodes contemporaneously; correlating means to correlate time periods within the set of data points from the motion sensor to cardiac activity reflected by the cardiac electrical signal; and setting means to store information indicating when data from the motion sensor is to be captured by reference to specific repeatable elements of the cardiac electrical signal. Illustrative collection means may take the form of a memory location for receiving data for at least temporary storage. The correlating means may take any suitable form for comparing two shapes such as a correlation waveform analysis block or signal processing chip, or a microprocessor or microcontroller with associated memory instructions for comparing two shapes by difference of area, principal components, or wavelet analysis, for example. The setting means may include a volatile or non-volatile memory. An example is in
An eighth non-limiting example is an ID as in the seventh non-limiting example, wherein the delay means is configured to calculate the delay period from the information stored by the setting means, taking into account a cardiac rate of the patient. A ninth non-limiting example is an ID as in any of the seventh or eight non-limiting examples, wherein: the correlating means is configured to determine when intrinsic mechanical motion of the heart is detected by the motion sensor relative to electrical signals of the heart; and the setting means is configured to store information indicating a time period relative to a specified electrical signal of the heart to avoid capturing intrinsic mechanical motion of the heart with the motion sensor. A tenth non-limiting example is an ID as in any of the seventh to ninth non-limiting examples, wherein the setting means is configured to set a delay to be triggered by detection of a T-wave in the cardiac electrical signal.
An eleventh non-limiting example is an ID as in any of the first to tenth non-limiting examples, wherein the ID includes pacing means to deliver pacing therapy to the patient and the predefined event is delivery of a pacing stimulus by the ID. Illustrative pacing means may include one or more of a voltage supply (such as an amplifier output), a current source (such as a current mirror), or a capacitor (or plurality thereof) or simply a battery output, coupled via the pulse generator module 104 (such as by a multiplexor, switch array or H-Bridge) to one or more of the electrodes 114, 114′, for example, and associated instruction sets for operation by the processing module 110.
A twelfth non-limiting example is an implantable device (ID) comprising a power source, operational circuitry, a motion sensor, and electrodes, the electrodes configured to capture a cardiac electrical signal, wherein the operational circuitry comprises: sampling means for sampling a signal from a motion sensor in the ID; baseline calculation means for analyzing the sampled signal over time to generate a baseline output of the motion sensor; present state means for determining a present state indicator from the sampled signal; comparing means to compare the present state indicator to the baseline to yield a difference; activity characterizing means to analyze the difference to determine the patient's activity level. Illustrative sampling means may be as described above. Illustrative baseline calculation means may include analog or digital domain memory or storage locations for capturing an average sampled output of the motion sensor over time, with associated instruction sets for the processing module 110 to use for controlling baseline. For example, block 306 (
Illustrative comparing means may include digital domain software instruction set or module for comparing two digital values, for example, or a comparator, for example, in the analog domain. A difference, as yielded, may be a subtractive difference, a ratio of two numbers/values, or other comparative output. Comparisons of this sort are noted at block 316 (
The activity characterizing means may include a state machine, for example, which operates to change state based on the difference as calculated by the comparing means, for example, assuming baseline to a rest state for the patient, then a difference such as large subtractive difference, or large ratio to the baseline would suggest a high level of activity and be classified in an active state if meeting an active state threshold; and if the difference is a small subtractive difference or ratio, below an inactive state threshold, then the state machine may assume an inactive state. Other such means may be provided, using for example a stored memory location as a characterization of patient activity with plural possible values such as active, inactive, or hysteresis (in-between). Illustratively, the Temporary Response Level (Temp RL, at
A thirteenth non-limiting example is an ID as in the twelfth non-limiting example, wherein the baseline calculation means uses a number, M, of individual samples from the motion sensor; the present state means uses a number, N, of individual samples from the motion sensor; and M is an order of magnitude larger than N.
A fourteenth non-limiting example is an ID as in any of the first to tenth, twelfth or thirteen non-limiting examples, wherein the operational circuitry comprises: pacing means to deliver pacing therapy to a patient at a pacing output rate; activity determining means configured to use an output of the motion sensor to calculate an activity level of the patient; and adjusting means to adjust the pacing output rate in view of the activity level. Such activity determining means may be as noted in block 1008 of
A fifteenth non-limiting example is an ID as in any of the first to fourteenth non-limiting examples, wherein the ID is configured as a leadless cardiac pacing device for implantation entirely within the heart of the patient without a lead.
A sixteenth non-limiting example is a method of operation in an implantable device comprising: initializing an implantable device (ID) for disposition within the heart of a patient, the ID comprising a motion sensor for detecting movement of the patient, the initializing step being performed by: contemporaneously collecting a set of data points from the motion sensor and from a cardiac electrical signal; correlating time periods within the set of data points from the motion sensor to cardiac activity reflected by the cardiac electrical signal; and configuring the ID to capture data from the motion sensor by reference to specific repeatable elements of the cardiac electrical signal; using the ID as configured in the initializing step to capture cardiac signals of the patient and motion signals for the patient. A seventeenth non-limiting example is a method as in the sixteenth non-limiting example, further comprising; using the motion signals to determine an activity level of the patient; and setting and implementing a pacing rate for the patient using the determined activity level.
An eighteenth non-limiting example is a method as in either of the sixteenth or seventeenth non-limiting examples, wherein the step of configuring the ID to capture data from the motion sensor is performed by: determining when intrinsic mechanical motion of the heart is detected by the motion sensor relative to electrical signals of the heart; and setting a data capture period for the motion sensor relative to a specified electrical signal of the heart to avoid capturing the intrinsic mechanical motion of the heart with the motion sensor.
A nineteenth non-limiting example is a method as in any of the sixteenth to eighteenth non-limiting examples, wherein the step of configuring the ID to capture data from the motion sensor includes determining a delay after a T-wave in the cardiac electrical signal. A twentieth non-limiting example is a method as in the nineteenth non-limiting example, wherein the delay is configured as a function of cardiac rate. A twenty-first non-limiting example is a method as in the twentieth non-limiting example, wherein the cardiac rate is determined as a rate of pacing output of the ID. A twenty-second non-limiting example is a method as in the twentieth non-limiting example, wherein the cardiac rate is determined as an intrinsic rate of the patient's heart.
A twenty-third non-limiting example is a method of operating a motion sensor in an implantable device (ID) for disposition within the heart of a patient, the ID comprising a motion sensor for detecting movement of the patient, the method comprising: the ID determining a predefined event has occurred in the heart of the patient; and the ID waiting a predetermined period of time after the predefined electrical event and sampling an output of the motion sensor.
A twenty-fourth non-limiting example is a method as in the twenty-third non-limiting example, further comprising duty cycling the motion sensor to operate in a window corresponding to the sampling step and otherwise be in a low-power state. A twenty-fifth non-limiting example is a method as in either of the twenty-third or twenty-fourth non-limiting examples, wherein the predefined event is one of an R-wave, a pacing pulse, or a QRS complex, and the predetermined time period is selected to expire prior to occurrence of a P-wave. A twenty-sixth non-limiting example is a method as in any of the twenty-third to twenty-fifth non-limiting examples, further comprising using the output of the motion sensor to determine whether the patient is physically active to facilitate a rate-responsive pacing by the ID. A twenty-seventh non-limiting example is a method as in any of the twenty-third to twenty-sixth non-limiting examples, further comprising using the output of the motion sensor to determine an increase or decrease in cardiac contractility to facilitate a rate-responsive pacing by the ID.
A twenty-eighth non-limiting example is a method as in any of the twenty-third to twenty-seventh non-limiting examples, further comprising determining the predetermined period of time by using an accepted formula for predicting occurrence of a cardiac mechanical or electrical event. A twenty-ninth non-limiting example is a method as in any of the twenty-third to twenty-seventh non-limiting examples further comprising determining the predetermined period of time by initializing the ID by capturing a plurality of outputs from the motion sensor over a period of time including several heart beats to determine a mechanically quiet period in the patient's cardiac cycle relative to the predefined event.
A thirtieth non-limiting example is a method as in any of the twenty-third to twenty-ninth non-limiting examples, wherein the predefined event is one of a P-wave, an R-wave, a QRS complex, a T-wave, or a quiescent period. A thirty-first non-limiting example is a method as in any of the twenty-third to twenty-ninth non-limiting examples wherein the predefined event is delivery of a pacing stimulus. A thirty-second non-limiting example is a method as in any of the twenty-third to thirty-first non-limiting examples, further comprising analyzing a cardiac electrical signal of the patient during at least the predetermined period of time to observe whether a specified cardiac electrical event occurs and, if so, discarding the sampled output of the motion sensor. A thirty-third non-limiting example is a method as in the thirty-second non-limiting example, wherein the specified cardiac event is a ventricular contraction. A thirty-fourth non-limiting example is a method as in the thirty-second non-limiting example, wherein occurrence of the ventricular contraction is determined by identifying a P-wave, R-wave or QRS complex in the electrical cardiac signal at the same time as, or just before, the output of the motion sensor is sampled.
A thirty-fifth non-limiting example is a method of determining whether a patient is active using an implantable device (ID) for disposition within the heart of a patient, the ID comprising a motion sensor for detecting movement of the patient, the method comprising: sampling a signal from a motion sensor in the ID; analyzing the sampled signal over time to generate a baseline; generating a present state indicator from the sampled signal; comparing the present state indicator to the baseline to yield a difference; and comparing the difference to one or more thresholds to characterize the patient's activity level.
A thirty-sixth non-limiting example is a method as in the thirty-fifth non-limiting example, wherein: the present state indicator is generated by averaging a number, M, of individual samples from the motion sensor; the subtractive baseline is generated by averaging a number, N, of individual samples from the motion sensor; and wherein M is an order of magnitude smaller than N. A thirty-seventh non-limiting example is a method as in either of the thirty-fifth or thirty-sixth non-limiting examples, further comprising: providing a pacing output from the ID to the patient's heart, wherein the pacing output has a rate which is adjustable; and adjusting the pacing output rate in light of the patient's activity level.
A thirty-eighth non-limiting example is a method of operating a motion sensor in an implantable device (ID) for disposition within the heart of a patient, the ID comprising a motion sensor for detecting movement of the patient, the method comprising: instructing a patient having the ID implanted in the heart thereof to adopt a set of postures or engage in a movement; capturing a number of motion sensor outputs while the patient is in one or more postures or engaging in one or more movement while capturing a cardiac electrical signal; identifying a quiet period within the cardiac the cardiac electrical signals during which intrinsic motion of the heart does not impact the output of the motion sensor outputs; and configuring the ID to activate and capture data from the motion sensor during the quiet periods. A thirty-ninth non-limiting example is a method as in the thirty-eighth non-limiting example, wherein the quiet time is defined relative to a predetermined event in the cardiac electrogram. A fortieth non-limiting example is a method comprising repeatedly performing the method of the thirty-eighth non-limiting example using one or more of the following: with and without the patient receiving pacing therapy; and for at least first and second postures or activities.
Each of these non-limiting examples can stand on its own, or can be combined in various permutations or combinations with one or more of the other examples. The above detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as “examples.” Such examples can include elements in addition to those shown or described. However, the present inventors also contemplate examples in which only those elements shown or described are provided. Moreover, the present inventors also contemplate examples using any combination or permutation of those elements shown or described (or one or more aspects thereof), either with respect to a particular example (or one or more aspects thereof), or with respect to other examples (or one or more aspects thereof) shown or described herein.
In the event of inconsistent usages between this document and any documents so incorporated by reference, the usage in this document controls. In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one, independent of any other instances or usages of “at least one” or “one or more.” Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.
Method examples described herein can be machine or computer-implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples. An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, in an example, the code can be tangibly stored on one or more volatile, non-transitory, or non-volatile tangible computer-readable media, such as during execution or at other times. Examples of these tangible computer-readable media can include, but are not limited to, hard disks, removable magnetic or optical disks, magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like.
The above description is intended to be illustrative, and not restrictive. For example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description.
The Abstract is provided to comply with 37 C.F.R. § 1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description as examples or embodiments, with each claim standing on its own as a separate embodiment, and it is contemplated that such embodiments can be combined with each other in various combinations or permutations. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
The present application is a divisional of U.S. patent application Ser. No. 15/243,524, filed Aug. 22, 2016, which claims the benefit of and priority to U.S. Provisional Patent Application Ser. No. 62/210,882, filed Aug. 27, 2015, the disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3835864 | Rasor et al. | Sep 1974 | A |
3943936 | Rasor et al. | Mar 1976 | A |
4142530 | Wittkampf | Mar 1979 | A |
4151513 | Menken et al. | Apr 1979 | A |
4157720 | Greatbatch | Jun 1979 | A |
RE30366 | Rasor et al. | Aug 1980 | E |
4250884 | Hartlaub et al. | Feb 1981 | A |
4256115 | Bilitch | Mar 1981 | A |
4263919 | Levin | Apr 1981 | A |
4310000 | Lindemans | Jan 1982 | A |
4312354 | Walters | Jan 1982 | A |
4323081 | Wiebusch | Apr 1982 | A |
4357946 | Dutcher et al. | Nov 1982 | A |
4365639 | Goldreyer | Dec 1982 | A |
4440173 | Kludziak et al. | Apr 1984 | A |
4476868 | Thompson | Oct 1984 | A |
4522208 | Buffet | Jun 1985 | A |
4556063 | Thompson et al. | Dec 1985 | A |
4562841 | Brockway et al. | Jan 1986 | A |
4593702 | Kepski et al. | Jun 1986 | A |
4593955 | Leiber | Jun 1986 | A |
4630611 | King | Dec 1986 | A |
4635639 | Hakala et al. | Jan 1987 | A |
4674508 | DeCote | Jun 1987 | A |
4712554 | Garson | Dec 1987 | A |
4729376 | DeCote | Mar 1988 | A |
4754753 | King | Jul 1988 | A |
4759366 | Callaghan | Jul 1988 | A |
4787389 | Tarjan | Nov 1988 | A |
4793353 | Borkan | Dec 1988 | A |
4819662 | Heil et al. | Apr 1989 | A |
4858610 | Callaghan et al. | Aug 1989 | A |
4886064 | Strandberg | Dec 1989 | A |
4928688 | Mower | May 1990 | A |
4967746 | Vandegriff | Nov 1990 | A |
4987897 | Funke | Jan 1991 | A |
4989602 | Sholder et al. | Feb 1991 | A |
5012806 | De Bellis | May 1991 | A |
5036849 | Hauck et al. | Aug 1991 | A |
5058581 | Silvian | Oct 1991 | A |
5078134 | Heilman et al. | Jan 1992 | A |
5109845 | Yuuchi et al. | May 1992 | A |
5113859 | Funke | May 1992 | A |
5117824 | Keimel et al. | Jun 1992 | A |
5127401 | Grevious et al. | Jul 1992 | A |
5133353 | Hauser | Jul 1992 | A |
5144950 | Stoop et al. | Sep 1992 | A |
5170784 | Ramon et al. | Dec 1992 | A |
5179945 | Van Hofwegen et al. | Jan 1993 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5193540 | Schulman et al. | Mar 1993 | A |
5241961 | Henry | Sep 1993 | A |
5243977 | Trabucco et al. | Sep 1993 | A |
5269326 | Verrier | Dec 1993 | A |
5284136 | Hauck et al. | Feb 1994 | A |
5300107 | Stokes et al. | Apr 1994 | A |
5301677 | Hsung | Apr 1994 | A |
5312439 | Loeb | May 1994 | A |
5313953 | Yomtov et al. | May 1994 | A |
5314459 | Swanson et al. | May 1994 | A |
5318597 | Hauck et al. | Jun 1994 | A |
5324316 | Schulman et al. | Jun 1994 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5334222 | Salo et al. | Aug 1994 | A |
5342408 | deCoriolis et al. | Aug 1994 | A |
5372606 | Lang et al. | Dec 1994 | A |
5376106 | Stahmann et al. | Dec 1994 | A |
5383915 | Adams | Jan 1995 | A |
5388578 | Yomtov et al. | Feb 1995 | A |
5404877 | Nolan et al. | Apr 1995 | A |
5405367 | Schulman et al. | Apr 1995 | A |
5411031 | Yomtov | May 1995 | A |
5411525 | Swanson et al. | May 1995 | A |
5411535 | Fujii et al. | May 1995 | A |
5456691 | Snell | Oct 1995 | A |
5466246 | Silvian | Nov 1995 | A |
5468254 | Hahn et al. | Nov 1995 | A |
5522866 | Fernald | Jun 1996 | A |
5540727 | Tockman et al. | Jul 1996 | A |
5545186 | Olson et al. | Aug 1996 | A |
5545202 | Dahl et al. | Aug 1996 | A |
5591214 | Lu | Jan 1997 | A |
5620466 | Haefner et al. | Apr 1997 | A |
5634938 | Swanson et al. | Jun 1997 | A |
5662688 | Haefner et al. | Sep 1997 | A |
5674259 | Gray | Oct 1997 | A |
5683426 | Greenhut et al. | Nov 1997 | A |
5683432 | Goedeke et al. | Nov 1997 | A |
5720770 | Nappholz et al. | Feb 1998 | A |
5728154 | Crossett et al. | Mar 1998 | A |
5741314 | Daly et al. | Apr 1998 | A |
5741315 | Lee et al. | Apr 1998 | A |
5752976 | Duffin et al. | May 1998 | A |
5752977 | Grevious et al. | May 1998 | A |
5755736 | Gillberg et al. | May 1998 | A |
5759199 | Snell et al. | Jun 1998 | A |
5774501 | Halpern et al. | Jun 1998 | A |
5792202 | Rueter | Aug 1998 | A |
5792203 | Schroeppel | Aug 1998 | A |
5792205 | Alt et al. | Aug 1998 | A |
5792208 | Gray | Aug 1998 | A |
5814089 | Stokes et al. | Sep 1998 | A |
5827216 | Igo et al. | Oct 1998 | A |
5836985 | Rostami et al. | Nov 1998 | A |
5836987 | Baumann et al. | Nov 1998 | A |
5842977 | Lesho et al. | Dec 1998 | A |
5855593 | Olson et al. | Jan 1999 | A |
5873894 | Vandegriff et al. | Feb 1999 | A |
5891184 | Lee et al. | Apr 1999 | A |
5897586 | Molina | Apr 1999 | A |
5899876 | Flower | May 1999 | A |
5899928 | Sholder et al. | May 1999 | A |
5919214 | Ciciarelli et al. | Jul 1999 | A |
5935078 | Feierbach | Aug 1999 | A |
5941906 | Barreras, Sr. et al. | Aug 1999 | A |
5954757 | Gray | Sep 1999 | A |
5978713 | Prutchi et al. | Nov 1999 | A |
5991660 | Goyal | Nov 1999 | A |
5999848 | Gord et al. | Dec 1999 | A |
5999857 | Weijand et al. | Dec 1999 | A |
6026320 | Carlson et al. | Feb 2000 | A |
6044298 | Salo et al. | Mar 2000 | A |
6044300 | Gray | Mar 2000 | A |
6055454 | Heemels | Apr 2000 | A |
6073050 | Griffith | Jun 2000 | A |
6076016 | Feierbach | Jun 2000 | A |
6080187 | Alt et al. | Jun 2000 | A |
6083248 | Thompson | Jul 2000 | A |
6106551 | Crossett et al. | Aug 2000 | A |
6115636 | Ryan | Sep 2000 | A |
6141581 | Olson et al. | Oct 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6141592 | Pauly | Oct 2000 | A |
6144879 | Gray | Nov 2000 | A |
6162195 | Igo et al. | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6167310 | Grevious | Dec 2000 | A |
6208894 | Schulman et al. | Mar 2001 | B1 |
6211799 | Post et al. | Apr 2001 | B1 |
6221011 | Bardy | Apr 2001 | B1 |
6240316 | Richmond et al. | May 2001 | B1 |
6240317 | Villaseca et al. | May 2001 | B1 |
6256534 | Dahl | Jul 2001 | B1 |
6259947 | Olson et al. | Jul 2001 | B1 |
6266558 | Gozani et al. | Jul 2001 | B1 |
6266567 | Ishikawa et al. | Jul 2001 | B1 |
6270457 | Bardy | Aug 2001 | B1 |
6272377 | Sweeney et al. | Aug 2001 | B1 |
6277072 | Bardy | Aug 2001 | B1 |
6280380 | Bardy | Aug 2001 | B1 |
6285907 | Kramer et al. | Sep 2001 | B1 |
6292698 | Duffin et al. | Sep 2001 | B1 |
6295473 | Rosar | Sep 2001 | B1 |
6298271 | Weijand | Oct 2001 | B1 |
6312378 | Bardy | Nov 2001 | B1 |
6315721 | Schulman et al. | Nov 2001 | B2 |
6336903 | Bardy | Jan 2002 | B1 |
6345202 | Richmond et al. | Feb 2002 | B2 |
6351667 | Godie | Feb 2002 | B1 |
6351669 | Hartley et al. | Feb 2002 | B1 |
6353759 | Hartley et al. | Mar 2002 | B1 |
6358203 | Bardy | Mar 2002 | B2 |
6361780 | Ley et al. | Mar 2002 | B1 |
6368284 | Bardy | Apr 2002 | B1 |
6371922 | Baumann et al. | Apr 2002 | B1 |
6398728 | Bardy | Jun 2002 | B1 |
6400982 | Sweeney et al. | Jun 2002 | B2 |
6400990 | Silvian | Jun 2002 | B1 |
6409674 | Brockway et al. | Jun 2002 | B1 |
6411848 | Kramer et al. | Jun 2002 | B2 |
6424865 | Ding | Jul 2002 | B1 |
6434429 | Kraus et al. | Aug 2002 | B1 |
6438410 | Hsu et al. | Aug 2002 | B2 |
6438417 | Rockwell et al. | Aug 2002 | B1 |
6438421 | Stahmann et al. | Aug 2002 | B1 |
6440066 | Bardy | Aug 2002 | B1 |
6441747 | Khair et al. | Aug 2002 | B1 |
6442426 | Kroll | Aug 2002 | B1 |
6442432 | Lee | Aug 2002 | B2 |
6443891 | Grevious | Sep 2002 | B1 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6453200 | Koslar | Sep 2002 | B1 |
6459929 | Hopper et al. | Oct 2002 | B1 |
6470215 | Kraus et al. | Oct 2002 | B1 |
6471645 | Warkentin et al. | Oct 2002 | B1 |
6480745 | Nelson et al. | Nov 2002 | B2 |
6487443 | Olson et al. | Nov 2002 | B2 |
6490487 | Kraus et al. | Dec 2002 | B1 |
6507755 | Gozani et al. | Jan 2003 | B1 |
6507759 | Prutchi et al. | Jan 2003 | B1 |
6512940 | Brabec et al. | Jan 2003 | B1 |
6522915 | Ceballos et al. | Feb 2003 | B1 |
6526311 | Begemann | Feb 2003 | B2 |
6542775 | Ding et al. | Apr 2003 | B2 |
6553258 | Stahmann et al. | Apr 2003 | B2 |
6561975 | Pool et al. | May 2003 | B1 |
6564807 | Schulman et al. | May 2003 | B1 |
6574506 | Kramer et al. | Jun 2003 | B2 |
6584352 | Combs et al. | Jun 2003 | B2 |
6597948 | Rockwell et al. | Jul 2003 | B1 |
6597951 | Kramer et al. | Jul 2003 | B2 |
6622046 | Fraley et al. | Sep 2003 | B2 |
6628985 | Sweeney et al. | Sep 2003 | B2 |
6647292 | Bardy et al. | Nov 2003 | B1 |
6666844 | Igo et al. | Dec 2003 | B1 |
6689117 | Sweeney et al. | Feb 2004 | B2 |
6690959 | Thompson | Feb 2004 | B2 |
6704602 | Berg et al. | Mar 2004 | B2 |
6718212 | Parry et al. | Apr 2004 | B2 |
6721597 | Bardy et al. | Apr 2004 | B1 |
6738670 | Almendinger et al. | May 2004 | B1 |
6749566 | Russ | Jun 2004 | B2 |
6758810 | Lebel et al. | Jul 2004 | B2 |
6763269 | Cox | Jul 2004 | B2 |
6778860 | Ostroff et al. | Aug 2004 | B2 |
6788971 | Sloman et al. | Sep 2004 | B1 |
6788974 | Bardy et al. | Sep 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
6847844 | Sun et al. | Jan 2005 | B2 |
6871095 | Stahmann et al. | Mar 2005 | B2 |
6878112 | Linberg et al. | Apr 2005 | B2 |
6885889 | Chinchoy | Apr 2005 | B2 |
6892094 | Ousdigian et al. | May 2005 | B2 |
6897788 | Khair et al. | May 2005 | B2 |
6904315 | Panken et al. | Jun 2005 | B2 |
6922592 | Thompson et al. | Jul 2005 | B2 |
6931282 | Esler | Aug 2005 | B2 |
6934585 | Schloss et al. | Aug 2005 | B1 |
6957107 | Rogers et al. | Oct 2005 | B2 |
6978176 | Lattouf | Dec 2005 | B2 |
6985773 | Von Arx et al. | Jan 2006 | B2 |
7003350 | Denker et al. | Feb 2006 | B2 |
7006864 | Echt et al. | Feb 2006 | B2 |
7013178 | Reinke et al. | Mar 2006 | B2 |
7027871 | Burnes et al. | Apr 2006 | B2 |
7050849 | Echt et al. | May 2006 | B2 |
7060031 | Webb et al. | Jun 2006 | B2 |
7063693 | Guenst | Jun 2006 | B2 |
7082336 | Ransbury et al. | Jul 2006 | B2 |
7085606 | Flach et al. | Aug 2006 | B2 |
7110824 | Amundson et al. | Sep 2006 | B2 |
7120504 | Osypka | Oct 2006 | B2 |
7139613 | Reinke et al. | Nov 2006 | B2 |
7142912 | Wagner et al. | Nov 2006 | B2 |
7146225 | Guenst et al. | Dec 2006 | B2 |
7146226 | Lau et al. | Dec 2006 | B2 |
7149581 | Goedeke | Dec 2006 | B2 |
7149588 | Lau et al. | Dec 2006 | B2 |
7158839 | Lau | Jan 2007 | B2 |
7162307 | Patrias | Jan 2007 | B2 |
7164952 | Lau et al. | Jan 2007 | B2 |
7177700 | Cox | Feb 2007 | B1 |
7181505 | Haller et al. | Feb 2007 | B2 |
7184830 | Echt et al. | Feb 2007 | B2 |
7186214 | Ness | Mar 2007 | B2 |
7191015 | Lamson et al. | Mar 2007 | B2 |
7200437 | Nabutovsky et al. | Apr 2007 | B1 |
7200439 | Zdeblick et al. | Apr 2007 | B2 |
7206423 | Feng et al. | Apr 2007 | B1 |
7209790 | Thompson et al. | Apr 2007 | B2 |
7212871 | Morgan | May 2007 | B1 |
7226440 | Gelfand et al. | Jun 2007 | B2 |
7228183 | Sun et al. | Jun 2007 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7236829 | Farazi et al. | Jun 2007 | B1 |
7254448 | Almendinger et al. | Aug 2007 | B2 |
7260436 | Kilgore et al. | Aug 2007 | B2 |
7270669 | Sra | Sep 2007 | B1 |
7272448 | Morgan et al. | Sep 2007 | B1 |
7277755 | Falkenberg et al. | Oct 2007 | B1 |
7280872 | Mosesov et al. | Oct 2007 | B1 |
7288096 | Chin | Oct 2007 | B2 |
7289847 | Gill et al. | Oct 2007 | B1 |
7289852 | Helfinstine et al. | Oct 2007 | B2 |
7289853 | Campbell et al. | Oct 2007 | B1 |
7289855 | Nghiem et al. | Oct 2007 | B2 |
7302294 | Kamath et al. | Nov 2007 | B2 |
7305266 | Kroll | Dec 2007 | B1 |
7310556 | Bulkes | Dec 2007 | B2 |
7319905 | Morgan et al. | Jan 2008 | B1 |
7333853 | Mazar et al. | Feb 2008 | B2 |
7336994 | Hettrick et al. | Feb 2008 | B2 |
7347819 | Lebel et al. | Mar 2008 | B2 |
7366572 | Heruth et al. | Apr 2008 | B2 |
7373207 | Lattouf | May 2008 | B2 |
7384403 | Sherman | Jun 2008 | B2 |
7386342 | Falkenberg et al. | Jun 2008 | B1 |
7392090 | Sweeney et al. | Jun 2008 | B2 |
7406105 | DelMain et al. | Jul 2008 | B2 |
7406349 | Seeberger et al. | Jul 2008 | B2 |
7410497 | Hastings et al. | Aug 2008 | B2 |
7425200 | Brockway et al. | Sep 2008 | B2 |
7433739 | Salys et al. | Oct 2008 | B1 |
7496409 | Greenhut et al. | Feb 2009 | B2 |
7496410 | Heil | Feb 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7512448 | Malick et al. | Mar 2009 | B2 |
7515969 | Tockman et al. | Apr 2009 | B2 |
7526342 | Chin et al. | Apr 2009 | B2 |
7529589 | Williams et al. | May 2009 | B2 |
7532933 | Hastings et al. | May 2009 | B2 |
7536222 | Bardy et al. | May 2009 | B2 |
7539541 | Quiles et al. | May 2009 | B2 |
7544197 | Kelsch et al. | Jun 2009 | B2 |
7558631 | Cowan et al. | Jul 2009 | B2 |
7565195 | Kroll et al. | Jul 2009 | B1 |
7584002 | Burnes et al. | Sep 2009 | B2 |
7590455 | Heruth et al. | Sep 2009 | B2 |
7606621 | Brisken et al. | Oct 2009 | B2 |
7610088 | Chinchoy | Oct 2009 | B2 |
7610092 | Cowan et al. | Oct 2009 | B2 |
7610099 | Almendinger et al. | Oct 2009 | B2 |
7610104 | Kaplan et al. | Oct 2009 | B2 |
7616991 | Mann et al. | Nov 2009 | B2 |
7617001 | Penner et al. | Nov 2009 | B2 |
7617007 | Williams et al. | Nov 2009 | B2 |
7630767 | Poore et al. | Dec 2009 | B1 |
7634313 | Kroll et al. | Dec 2009 | B1 |
7637867 | Zdeblick | Dec 2009 | B2 |
7640060 | Zdeblick | Dec 2009 | B2 |
7647109 | Hastings et al. | Jan 2010 | B2 |
7650186 | Hastings et al. | Jan 2010 | B2 |
7657311 | Bardy et al. | Feb 2010 | B2 |
7668596 | Von Arx et al. | Feb 2010 | B2 |
7691047 | Ferrari | Apr 2010 | B2 |
7702392 | Echt et al. | Apr 2010 | B2 |
7713194 | Zdeblick | May 2010 | B2 |
7713195 | Zdeblick | May 2010 | B2 |
7729783 | Michels et al. | Jun 2010 | B2 |
7734333 | Ghanem et al. | Jun 2010 | B2 |
7734343 | Ransbury et al. | Jun 2010 | B2 |
7738958 | Zdeblick et al. | Jun 2010 | B2 |
7738964 | Von Arx et al. | Jun 2010 | B2 |
7742812 | Ghanem et al. | Jun 2010 | B2 |
7742816 | Masoud et al. | Jun 2010 | B2 |
7742822 | Masoud et al. | Jun 2010 | B2 |
7743151 | Vallapureddy et al. | Jun 2010 | B2 |
7747335 | Williams | Jun 2010 | B2 |
7751881 | Cowan et al. | Jul 2010 | B2 |
7758521 | Morris et al. | Jul 2010 | B2 |
7761150 | Ghanem et al. | Jul 2010 | B2 |
7761164 | Verhoef et al. | Jul 2010 | B2 |
7765001 | Echt et al. | Jul 2010 | B2 |
7769452 | Ghanem et al. | Aug 2010 | B2 |
7778699 | Ferrise et al. | Aug 2010 | B1 |
7792588 | Harding | Sep 2010 | B2 |
7797059 | Bornzin et al. | Sep 2010 | B1 |
7801596 | Fischell et al. | Sep 2010 | B2 |
7809438 | Echt et al. | Oct 2010 | B2 |
7840281 | Kveen et al. | Nov 2010 | B2 |
7844348 | Swoyer et al. | Nov 2010 | B2 |
7846088 | Ness | Dec 2010 | B2 |
7848815 | Brisken et al. | Dec 2010 | B2 |
7848823 | Drasler et al. | Dec 2010 | B2 |
7860455 | Fukumoto et al. | Dec 2010 | B2 |
7871433 | Lattouf | Jan 2011 | B2 |
7877136 | Moffitt et al. | Jan 2011 | B1 |
7877142 | Moaddeb et al. | Jan 2011 | B2 |
7881798 | Miesel et al. | Feb 2011 | B2 |
7881810 | Chitre et al. | Feb 2011 | B1 |
7890173 | Brisken et al. | Feb 2011 | B2 |
7890181 | Denzene et al. | Feb 2011 | B2 |
7890192 | Kelsch et al. | Feb 2011 | B1 |
7894894 | Stadler et al. | Feb 2011 | B2 |
7894907 | Cowan et al. | Feb 2011 | B2 |
7894910 | Cowan et al. | Feb 2011 | B2 |
7894915 | Chitre et al. | Feb 2011 | B1 |
7899537 | Kroll et al. | Mar 2011 | B1 |
7899541 | Cowan et al. | Mar 2011 | B2 |
7899542 | Cowan et al. | Mar 2011 | B2 |
7899554 | Williams et al. | Mar 2011 | B2 |
7901360 | Yang et al. | Mar 2011 | B1 |
7904170 | Harding | Mar 2011 | B2 |
7907993 | Ghanem et al. | Mar 2011 | B2 |
7920928 | Yang et al. | Apr 2011 | B1 |
7925343 | Min et al. | Apr 2011 | B1 |
7930040 | Kelsch et al. | Apr 2011 | B1 |
7937135 | Ghanem et al. | May 2011 | B2 |
7937148 | Jacobson | May 2011 | B2 |
7937161 | Hastings et al. | May 2011 | B2 |
7941214 | Kleckner et al. | May 2011 | B2 |
7945333 | Jacobson | May 2011 | B2 |
7946997 | Hübinette | May 2011 | B2 |
7949404 | Hill | May 2011 | B2 |
7949405 | Feher | May 2011 | B2 |
7953493 | Fowler et al. | May 2011 | B2 |
7962202 | Bhunia | Jun 2011 | B2 |
7974702 | Fain et al. | Jul 2011 | B1 |
7979136 | Young et al. | Jul 2011 | B2 |
7983753 | Severin | Jul 2011 | B2 |
7991467 | Markowitz et al. | Aug 2011 | B2 |
7991471 | Ghanem et al. | Aug 2011 | B2 |
7996087 | Cowan et al. | Aug 2011 | B2 |
8000791 | Sunagawa et al. | Aug 2011 | B2 |
8000807 | Morris et al. | Aug 2011 | B2 |
8001975 | DiSilvestro et al. | Aug 2011 | B2 |
8002700 | Ferek-Petric et al. | Aug 2011 | B2 |
8010209 | Jacobson | Aug 2011 | B2 |
8019419 | Panescu et al. | Sep 2011 | B1 |
8019434 | Quiles et al. | Sep 2011 | B2 |
8027727 | Freeberg | Sep 2011 | B2 |
8027729 | Sunagawa et al. | Sep 2011 | B2 |
8032219 | Neumann et al. | Oct 2011 | B2 |
8036743 | Savage et al. | Oct 2011 | B2 |
8046079 | Bange et al. | Oct 2011 | B2 |
8046080 | Von Arx et al. | Oct 2011 | B2 |
8050297 | DelMain et al. | Nov 2011 | B2 |
8050759 | Stegemann et al. | Nov 2011 | B2 |
8050774 | Kveen et al. | Nov 2011 | B2 |
8055345 | Li et al. | Nov 2011 | B2 |
8055350 | Roberts | Nov 2011 | B2 |
8060212 | Rios et al. | Nov 2011 | B1 |
8065018 | Haubrich et al. | Nov 2011 | B2 |
8073542 | Doerr | Dec 2011 | B2 |
8078278 | Penner | Dec 2011 | B2 |
8078283 | Cowan et al. | Dec 2011 | B2 |
8095123 | Gray | Jan 2012 | B2 |
8102789 | Rosar et al. | Jan 2012 | B2 |
8103359 | Reddy | Jan 2012 | B2 |
8103361 | Moser | Jan 2012 | B2 |
8112148 | Giftakis et al. | Feb 2012 | B2 |
8114021 | Robertson et al. | Feb 2012 | B2 |
8121680 | Falkenberg et al. | Feb 2012 | B2 |
8123684 | Zdeblick | Feb 2012 | B2 |
8126545 | Flach et al. | Feb 2012 | B2 |
8131334 | Lu et al. | Mar 2012 | B2 |
8140161 | Willerton et al. | Mar 2012 | B2 |
8150521 | Crowley et al. | Apr 2012 | B2 |
8160672 | Kim et al. | Apr 2012 | B2 |
8160702 | Mann et al. | Apr 2012 | B2 |
8160704 | Freeberg | Apr 2012 | B2 |
8165694 | Carbanaru et al. | Apr 2012 | B2 |
8175715 | Cox | May 2012 | B1 |
8180451 | Hickman et al. | May 2012 | B2 |
8185213 | Kveen et al. | May 2012 | B2 |
8187161 | Li et al. | May 2012 | B2 |
8204595 | Pianca et al. | Jun 2012 | B2 |
8204605 | Hastings et al. | Jun 2012 | B2 |
8209014 | Doerr | Jun 2012 | B2 |
8214043 | Matos | Jul 2012 | B2 |
8224244 | Kim et al. | Jul 2012 | B2 |
8233985 | Bulkes et al. | Jul 2012 | B2 |
8265748 | Liu et al. | Sep 2012 | B2 |
8265757 | Mass et al. | Sep 2012 | B2 |
8280521 | Haubrich et al. | Oct 2012 | B2 |
8285387 | Utsi et al. | Oct 2012 | B2 |
8290598 | Boon et al. | Oct 2012 | B2 |
8290600 | Hastings et al. | Oct 2012 | B2 |
8295939 | Jacobson | Oct 2012 | B2 |
8301254 | Mosesov et al. | Oct 2012 | B2 |
8315701 | Cowan et al. | Nov 2012 | B2 |
8315708 | Berthelsdorf et al. | Nov 2012 | B2 |
8321021 | Kisker et al. | Nov 2012 | B2 |
8321036 | Brockway et al. | Nov 2012 | B2 |
8332036 | Hastings et al. | Dec 2012 | B2 |
8335563 | Stessman | Dec 2012 | B2 |
8335568 | Heruth et al. | Dec 2012 | B2 |
8340750 | Prakash et al. | Dec 2012 | B2 |
8340780 | Hastings et al. | Dec 2012 | B2 |
8352025 | Jacobson | Jan 2013 | B2 |
8352028 | Wenger | Jan 2013 | B2 |
8352038 | Mao et al. | Jan 2013 | B2 |
8359098 | Lund et al. | Jan 2013 | B2 |
8364276 | Willis | Jan 2013 | B2 |
8369959 | Meskens | Feb 2013 | B2 |
8369962 | Abrahamson | Feb 2013 | B2 |
8380320 | Spital | Feb 2013 | B2 |
8386051 | Rys | Feb 2013 | B2 |
8391981 | Mosesov | Mar 2013 | B2 |
8391990 | Smith et al. | Mar 2013 | B2 |
8406874 | Liu et al. | Mar 2013 | B2 |
8406886 | Gaunt et al. | Mar 2013 | B2 |
8412352 | Griswold et al. | Apr 2013 | B2 |
8417340 | Goossen | Apr 2013 | B2 |
8417341 | Freeberg | Apr 2013 | B2 |
8423149 | Hennig | Apr 2013 | B2 |
8428722 | Verhoef et al. | Apr 2013 | B2 |
8433402 | Ruben et al. | Apr 2013 | B2 |
8433409 | Johnson et al. | Apr 2013 | B2 |
8433420 | Bange et al. | Apr 2013 | B2 |
8447412 | Dal Molin et al. | May 2013 | B2 |
8452413 | Young et al. | May 2013 | B2 |
8457740 | Osche | Jun 2013 | B2 |
8457742 | Jacobson | Jun 2013 | B2 |
8457761 | Wariar | Jun 2013 | B2 |
8478407 | Demmer et al. | Jul 2013 | B2 |
8478408 | Hastings et al. | Jul 2013 | B2 |
8478431 | Griswold et al. | Jul 2013 | B2 |
8504156 | Bonner et al. | Aug 2013 | B2 |
8509910 | Sowder et al. | Aug 2013 | B2 |
8515559 | Roberts et al. | Aug 2013 | B2 |
8527068 | Ostroff | Sep 2013 | B2 |
8532790 | Griswold | Sep 2013 | B2 |
8541131 | Lund et al. | Sep 2013 | B2 |
8543205 | Ostroff | Sep 2013 | B2 |
8547248 | Zdeblick et al. | Oct 2013 | B2 |
8548605 | Ollivier | Oct 2013 | B2 |
8554333 | Wu et al. | Oct 2013 | B2 |
8565878 | Allavatam et al. | Oct 2013 | B2 |
8565882 | Mates | Oct 2013 | B2 |
8565897 | Regnier et al. | Oct 2013 | B2 |
8571678 | Wang | Oct 2013 | B2 |
8577327 | Makdissi et al. | Nov 2013 | B2 |
8588926 | Moore et al. | Nov 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8615310 | Khairkhahan et al. | Dec 2013 | B2 |
8626294 | Sheldon et al. | Jan 2014 | B2 |
8634908 | Cowan | Jan 2014 | B2 |
8634912 | Bornzin et al. | Jan 2014 | B2 |
8634919 | Hou et al. | Jan 2014 | B1 |
8639335 | Peichel et al. | Jan 2014 | B2 |
8644934 | Hastings et al. | Feb 2014 | B2 |
8649859 | Smith et al. | Feb 2014 | B2 |
8670842 | Bornzin et al. | Mar 2014 | B1 |
8676319 | Knoll | Mar 2014 | B2 |
8676335 | Katoozi et al. | Mar 2014 | B2 |
8700173 | Edlund | Apr 2014 | B2 |
8700181 | Bornzin et al. | Apr 2014 | B2 |
8705599 | dal Molin et al. | Apr 2014 | B2 |
8718773 | Willis et al. | May 2014 | B2 |
8738147 | Hastings et al. | May 2014 | B2 |
8744572 | Greenhut et al. | Jun 2014 | B1 |
8747314 | Stahmann et al. | Jun 2014 | B2 |
8755884 | Demmer et al. | Jun 2014 | B2 |
8758365 | Bonner et al. | Jun 2014 | B2 |
8774572 | Hamamoto | Jul 2014 | B2 |
8781605 | Bornzin et al. | Jul 2014 | B2 |
8788035 | Jacobson | Jul 2014 | B2 |
8788053 | Jacobson | Jul 2014 | B2 |
8798740 | Samade et al. | Aug 2014 | B2 |
8798745 | Jacobson | Aug 2014 | B2 |
8798762 | Fain et al. | Aug 2014 | B2 |
8798770 | Reddy | Aug 2014 | B2 |
8805505 | Roberts | Aug 2014 | B1 |
8805528 | Corndorf | Aug 2014 | B2 |
8812109 | Blomqvist et al. | Aug 2014 | B2 |
8818504 | Bodner et al. | Aug 2014 | B2 |
8831747 | Min et al. | Sep 2014 | B1 |
8855789 | Jacobson | Oct 2014 | B2 |
8868186 | Kroll | Oct 2014 | B2 |
8886339 | Faltys et al. | Nov 2014 | B2 |
8903500 | Smith et al. | Dec 2014 | B2 |
8903513 | Ollivier | Dec 2014 | B2 |
8914131 | Bornzin et al. | Dec 2014 | B2 |
8923795 | Makdissi et al. | Dec 2014 | B2 |
8923963 | Bonner et al. | Dec 2014 | B2 |
8938300 | Rosero | Jan 2015 | B2 |
8942806 | Sheldon et al. | Jan 2015 | B2 |
8958892 | Khairkhahan et al. | Feb 2015 | B2 |
8977358 | Ewert et al. | Mar 2015 | B2 |
8989873 | Locsin | Mar 2015 | B2 |
8996109 | Karst et al. | Mar 2015 | B2 |
9002467 | Smith et al. | Apr 2015 | B2 |
9008776 | Cowan et al. | Apr 2015 | B2 |
9008777 | Dianaty et al. | Apr 2015 | B2 |
9014818 | Deterre et al. | Apr 2015 | B2 |
9017341 | Bornzin et al. | Apr 2015 | B2 |
9020611 | Khairkhahan et al. | Apr 2015 | B2 |
9037262 | Regnier et al. | May 2015 | B2 |
9042984 | Demmer et al. | May 2015 | B2 |
9072911 | Hastings et al. | Jul 2015 | B2 |
9072913 | Jacobson | Jul 2015 | B2 |
9155882 | Grubac et al. | Oct 2015 | B2 |
9168372 | Fain | Oct 2015 | B2 |
9168380 | Greenhut et al. | Oct 2015 | B1 |
9168383 | Jacobson et al. | Oct 2015 | B2 |
9180285 | Moore et al. | Nov 2015 | B2 |
9192774 | Jacobson | Nov 2015 | B2 |
9205225 | Khairkhahan et al. | Dec 2015 | B2 |
9216285 | Boling et al. | Dec 2015 | B1 |
9216293 | Berthiaume et al. | Dec 2015 | B2 |
9216298 | Jacobson | Dec 2015 | B2 |
9227077 | Jacobson | Jan 2016 | B2 |
9238145 | Wenzel et al. | Jan 2016 | B2 |
9242102 | Khairkhahan et al. | Jan 2016 | B2 |
9242113 | Smith et al. | Jan 2016 | B2 |
9248300 | Rys et al. | Feb 2016 | B2 |
9265436 | Min et al. | Feb 2016 | B2 |
9265962 | Dianaty et al. | Feb 2016 | B2 |
9272155 | Ostroff | Mar 2016 | B2 |
9278218 | Karst et al. | Mar 2016 | B2 |
9278229 | Reinke et al. | Mar 2016 | B1 |
9283381 | Grubac et al. | Mar 2016 | B2 |
9283382 | Berthiaume et al. | Mar 2016 | B2 |
9289612 | Sambelashvili et al. | Mar 2016 | B1 |
9302115 | Molin et al. | Apr 2016 | B2 |
9333364 | Echt et al. | May 2016 | B2 |
9358387 | Suwito et al. | Jun 2016 | B2 |
9358400 | Jacobson | Jun 2016 | B2 |
9364675 | Deterre et al. | Jun 2016 | B2 |
9370663 | Moulder | Jun 2016 | B2 |
9375580 | Bonner et al. | Jun 2016 | B2 |
9375581 | Baru et al. | Jun 2016 | B2 |
9381365 | Kibler et al. | Jul 2016 | B2 |
9393424 | Demmer et al. | Jul 2016 | B2 |
9393436 | Doerr | Jul 2016 | B2 |
9399139 | Demmer et al. | Jul 2016 | B2 |
9399140 | Cho et al. | Jul 2016 | B2 |
9409033 | Jacobson | Aug 2016 | B2 |
9427594 | Bornzin et al. | Aug 2016 | B1 |
9433368 | Stahmann et al. | Sep 2016 | B2 |
9433780 | Régnier et al. | Sep 2016 | B2 |
9517017 | Shuros | Dec 2016 | B2 |
9814406 | Razavi | Nov 2017 | B2 |
9956414 | Kane et al. | May 2018 | B2 |
20020032470 | Linberg | Mar 2002 | A1 |
20020035376 | Bardy et al. | Mar 2002 | A1 |
20020035377 | Bardy et al. | Mar 2002 | A1 |
20020035378 | Bardy et al. | Mar 2002 | A1 |
20020035380 | Rissmann et al. | Mar 2002 | A1 |
20020035381 | Bardy et al. | Mar 2002 | A1 |
20020042629 | Bardy et al. | Apr 2002 | A1 |
20020042630 | Bardy et al. | Apr 2002 | A1 |
20020042634 | Bardy et al. | Apr 2002 | A1 |
20020049475 | Bardy et al. | Apr 2002 | A1 |
20020052636 | Bardy et al. | May 2002 | A1 |
20020068958 | Bardy et al. | Jun 2002 | A1 |
20020072773 | Bardy et al. | Jun 2002 | A1 |
20020082665 | Haller et al. | Jun 2002 | A1 |
20020091414 | Bardy et al. | Jul 2002 | A1 |
20020095196 | Linberg | Jul 2002 | A1 |
20020099423 | Berg et al. | Jul 2002 | A1 |
20020103510 | Bardy et al. | Aug 2002 | A1 |
20020107545 | Rissmann et al. | Aug 2002 | A1 |
20020107546 | Ostroff et al. | Aug 2002 | A1 |
20020107547 | Erlinger et al. | Aug 2002 | A1 |
20020107548 | Bardy et al. | Aug 2002 | A1 |
20020107549 | Bardy et al. | Aug 2002 | A1 |
20020107559 | Sanders et al. | Aug 2002 | A1 |
20020120299 | Ostroff et al. | Aug 2002 | A1 |
20020173830 | Starkweather et al. | Nov 2002 | A1 |
20020193846 | Pool et al. | Dec 2002 | A1 |
20030009203 | Lebel et al. | Jan 2003 | A1 |
20030028082 | Thompson | Feb 2003 | A1 |
20030041866 | Linberg et al. | Mar 2003 | A1 |
20030088278 | Bardy et al. | May 2003 | A1 |
20030097153 | Bardy et al. | May 2003 | A1 |
20030114908 | Flach | Jun 2003 | A1 |
20030144701 | Mehra et al. | Jul 2003 | A1 |
20030187460 | Chin et al. | Oct 2003 | A1 |
20030187461 | Chin | Oct 2003 | A1 |
20040024435 | Leckrone et al. | Feb 2004 | A1 |
20040087938 | Leckrone et al. | May 2004 | A1 |
20040088035 | Guenst et al. | May 2004 | A1 |
20040102830 | Williams | May 2004 | A1 |
20040127959 | Amundson et al. | Jul 2004 | A1 |
20040147969 | Mann et al. | Jul 2004 | A1 |
20040147973 | Hauser | Jul 2004 | A1 |
20040167558 | Igo et al. | Aug 2004 | A1 |
20040167587 | Thompson | Aug 2004 | A1 |
20040172071 | Bardy et al. | Sep 2004 | A1 |
20040172077 | Chinchoy | Sep 2004 | A1 |
20040172104 | Berg et al. | Sep 2004 | A1 |
20040176817 | Wahlstrand et al. | Sep 2004 | A1 |
20040176818 | Wahlstrand et al. | Sep 2004 | A1 |
20040176830 | Fang | Sep 2004 | A1 |
20040186529 | Bardy et al. | Sep 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040210292 | Bardy et al. | Oct 2004 | A1 |
20040210293 | Bardy et al. | Oct 2004 | A1 |
20040210294 | Bardy et al. | Oct 2004 | A1 |
20040215308 | Bardy et al. | Oct 2004 | A1 |
20040220626 | Wagner | Nov 2004 | A1 |
20040220639 | Mulligan et al. | Nov 2004 | A1 |
20040249431 | Ransbury et al. | Dec 2004 | A1 |
20040267303 | Guenst | Dec 2004 | A1 |
20050061320 | Lee et al. | Mar 2005 | A1 |
20050070962 | Echt et al. | Mar 2005 | A1 |
20050102003 | Grabek et al. | May 2005 | A1 |
20050149138 | Min et al. | Jul 2005 | A1 |
20050165466 | Morris et al. | Jul 2005 | A1 |
20050182465 | Ness | Aug 2005 | A1 |
20050203410 | Jenkins | Sep 2005 | A1 |
20050283208 | Arx et al. | Dec 2005 | A1 |
20060052829 | Sun et al. | Mar 2006 | A1 |
20060052830 | Spinelli et al. | Mar 2006 | A1 |
20060064135 | Brockway | Mar 2006 | A1 |
20060064149 | Belacazar et al. | Mar 2006 | A1 |
20060085039 | Hastings et al. | Apr 2006 | A1 |
20060085041 | Hastings et al. | Apr 2006 | A1 |
20060085042 | Hastings et al. | Apr 2006 | A1 |
20060095078 | Tronnes | May 2006 | A1 |
20060106442 | Richardson et al. | May 2006 | A1 |
20060116746 | Chin | Jun 2006 | A1 |
20060135999 | Bodner et al. | Jun 2006 | A1 |
20060136004 | Cowan et al. | Jun 2006 | A1 |
20060161061 | Echt et al. | Jul 2006 | A1 |
20060200002 | Guenst | Sep 2006 | A1 |
20060206151 | Lu | Sep 2006 | A1 |
20060212079 | Routh et al. | Sep 2006 | A1 |
20060241701 | Markowitz et al. | Oct 2006 | A1 |
20060241705 | Neumann et al. | Oct 2006 | A1 |
20060247672 | Vidlund et al. | Nov 2006 | A1 |
20060259088 | Pastore et al. | Nov 2006 | A1 |
20060265018 | Smith et al. | Nov 2006 | A1 |
20070004979 | Wojciechowicz et al. | Jan 2007 | A1 |
20070027508 | Cowan | Feb 2007 | A1 |
20070078490 | Cowan et al. | Apr 2007 | A1 |
20070088394 | Jacobson | Apr 2007 | A1 |
20070088396 | Jacobson | Apr 2007 | A1 |
20070088397 | Jacobson | Apr 2007 | A1 |
20070088398 | Jacobson | Apr 2007 | A1 |
20070088405 | Jacobson | Apr 2007 | A1 |
20070118054 | Pinhas et al. | May 2007 | A1 |
20070135882 | Drasler et al. | Jun 2007 | A1 |
20070135883 | Drasler et al. | Jun 2007 | A1 |
20070150037 | Hastings et al. | Jun 2007 | A1 |
20070150038 | Hastings et al. | Jun 2007 | A1 |
20070156190 | Cinbis | Jul 2007 | A1 |
20070219525 | Gelfand et al. | Sep 2007 | A1 |
20070219590 | Hastings et al. | Sep 2007 | A1 |
20070225545 | Ferrari | Sep 2007 | A1 |
20070233206 | Frikart et al. | Oct 2007 | A1 |
20070239244 | Morgan et al. | Oct 2007 | A1 |
20070255327 | Cho et al. | Nov 2007 | A1 |
20070255376 | Michels et al. | Nov 2007 | A1 |
20070276444 | Gelbart et al. | Nov 2007 | A1 |
20070293900 | Sheldon et al. | Dec 2007 | A1 |
20070293904 | Gelbart et al. | Dec 2007 | A1 |
20080004663 | Jorgenson | Jan 2008 | A1 |
20080021505 | Hastings et al. | Jan 2008 | A1 |
20080021519 | De Geest et al. | Jan 2008 | A1 |
20080021532 | Kveen et al. | Jan 2008 | A1 |
20080065185 | Worley | Mar 2008 | A1 |
20080071318 | Brooke et al. | Mar 2008 | A1 |
20080109054 | Hastings et al. | May 2008 | A1 |
20080119911 | Rosero | May 2008 | A1 |
20080130670 | Kim et al. | Jun 2008 | A1 |
20080154322 | Jackson et al. | Jun 2008 | A1 |
20080228234 | Stancer | Sep 2008 | A1 |
20080234771 | Chinchoy et al. | Sep 2008 | A1 |
20080243217 | Wildon | Oct 2008 | A1 |
20080269814 | Rosero | Oct 2008 | A1 |
20080269825 | Chinchoy et al. | Oct 2008 | A1 |
20080275518 | Ghanem et al. | Nov 2008 | A1 |
20080275519 | Ghanem et al. | Nov 2008 | A1 |
20080288039 | Reddy | Nov 2008 | A1 |
20080294208 | Willis et al. | Nov 2008 | A1 |
20080294210 | Rosero | Nov 2008 | A1 |
20080306359 | Zdeblick et al. | Dec 2008 | A1 |
20090018599 | Hastings et al. | Jan 2009 | A1 |
20090024180 | Kisker et al. | Jan 2009 | A1 |
20090036941 | Corbucci | Feb 2009 | A1 |
20090048646 | Katoozi et al. | Feb 2009 | A1 |
20090062895 | Stahmann et al. | Mar 2009 | A1 |
20090082827 | Kveen et al. | Mar 2009 | A1 |
20090082828 | Ostroff | Mar 2009 | A1 |
20090088813 | Brockway et al. | Apr 2009 | A1 |
20090131907 | Chin et al. | May 2009 | A1 |
20090135886 | Robertson et al. | May 2009 | A1 |
20090143835 | Pastore et al. | Jun 2009 | A1 |
20090171408 | Solem | Jul 2009 | A1 |
20090171414 | Kelly et al. | Jul 2009 | A1 |
20090204170 | Hastings et al. | Aug 2009 | A1 |
20090210024 | Brooke | Aug 2009 | A1 |
20090216292 | Pless et al. | Aug 2009 | A1 |
20090234407 | Hastings et al. | Sep 2009 | A1 |
20090234411 | Sambelashvili et al. | Sep 2009 | A1 |
20090275998 | Burnes et al. | Nov 2009 | A1 |
20090275999 | Burnes et al. | Nov 2009 | A1 |
20090299447 | Jensen et al. | Dec 2009 | A1 |
20100013668 | Kantervik | Jan 2010 | A1 |
20100016911 | Willis et al. | Jan 2010 | A1 |
20100023085 | Wu et al. | Jan 2010 | A1 |
20100030061 | Canfield et al. | Feb 2010 | A1 |
20100030327 | Chatel | Feb 2010 | A1 |
20100042108 | Hibino | Feb 2010 | A1 |
20100056871 | Govari et al. | Mar 2010 | A1 |
20100063375 | Kassab et al. | Mar 2010 | A1 |
20100063562 | Cowan et al. | Mar 2010 | A1 |
20100094367 | Sen | Apr 2010 | A1 |
20100114209 | Krause et al. | May 2010 | A1 |
20100125281 | Jacobson et al. | May 2010 | A1 |
20100168761 | Kassab et al. | Jul 2010 | A1 |
20100168819 | Freeberg | Jul 2010 | A1 |
20100198288 | Ostroff | Aug 2010 | A1 |
20100198304 | Wang | Aug 2010 | A1 |
20100217367 | Belson | Aug 2010 | A1 |
20100228308 | Cowan et al. | Sep 2010 | A1 |
20100234924 | Willis | Sep 2010 | A1 |
20100241185 | Mahapatra et al. | Sep 2010 | A1 |
20100249729 | Morris et al. | Sep 2010 | A1 |
20100286744 | Echt et al. | Nov 2010 | A1 |
20100312309 | Harding | Dec 2010 | A1 |
20110022113 | Zdeblick et al. | Jan 2011 | A1 |
20110071586 | Jacobson | Mar 2011 | A1 |
20110077708 | Ostroff | Mar 2011 | A1 |
20110112600 | Cowan et al. | May 2011 | A1 |
20110118588 | Komblau et al. | May 2011 | A1 |
20110118810 | Cowan et al. | May 2011 | A1 |
20110137187 | Yang et al. | Jun 2011 | A1 |
20110144720 | Cowan et al. | Jun 2011 | A1 |
20110152970 | Jollota et al. | Jun 2011 | A1 |
20110160565 | Stubbs et al. | Jun 2011 | A1 |
20110160801 | Markowitz et al. | Jun 2011 | A1 |
20110160806 | Lyden et al. | Jun 2011 | A1 |
20110166620 | Cowan et al. | Jul 2011 | A1 |
20110166621 | Cowan et al. | Jul 2011 | A1 |
20110184491 | Kivi | Jul 2011 | A1 |
20110190835 | Brockway et al. | Aug 2011 | A1 |
20110208260 | Jacobson | Aug 2011 | A1 |
20110218587 | Jacobson | Sep 2011 | A1 |
20110230734 | Fain et al. | Sep 2011 | A1 |
20110237967 | Moore et al. | Sep 2011 | A1 |
20110245890 | Brisben et al. | Oct 2011 | A1 |
20110251660 | Griswold | Oct 2011 | A1 |
20110251662 | Griswold et al. | Oct 2011 | A1 |
20110270099 | Ruben et al. | Nov 2011 | A1 |
20110270339 | Murray, III et al. | Nov 2011 | A1 |
20110270340 | Pellegrini et al. | Nov 2011 | A1 |
20110276102 | Cohen | Nov 2011 | A1 |
20110282423 | Jacobson | Nov 2011 | A1 |
20120004527 | Thompson et al. | Jan 2012 | A1 |
20120029323 | Zhao | Feb 2012 | A1 |
20120041508 | Rousso et al. | Feb 2012 | A1 |
20120059433 | Cowan et al. | Mar 2012 | A1 |
20120059436 | Fontaine et al. | Mar 2012 | A1 |
20120078322 | Molin et al. | Mar 2012 | A1 |
20120089198 | Ostroff | Apr 2012 | A1 |
20120093245 | Makdissi et al. | Apr 2012 | A1 |
20120095521 | Hintz | Apr 2012 | A1 |
20120095539 | Khairkhahan et al. | Apr 2012 | A1 |
20120101540 | O'Brien et al. | Apr 2012 | A1 |
20120101553 | Reddy | Apr 2012 | A1 |
20120109148 | Bonner et al. | May 2012 | A1 |
20120109149 | Bonner et al. | May 2012 | A1 |
20120109236 | Jacobson et al. | May 2012 | A1 |
20120109259 | Bond et al. | May 2012 | A1 |
20120116489 | Khairkhahan et al. | May 2012 | A1 |
20120150251 | Giftakis et al. | Jun 2012 | A1 |
20120158111 | Khairkhahan et al. | Jun 2012 | A1 |
20120165827 | Khairkhahan et al. | Jun 2012 | A1 |
20120172690 | Anderson et al. | Jul 2012 | A1 |
20120172891 | Lee | Jul 2012 | A1 |
20120172892 | Grubac et al. | Jul 2012 | A1 |
20120172942 | Berg | Jul 2012 | A1 |
20120197350 | Roberts et al. | Aug 2012 | A1 |
20120197373 | Khairkhahan et al. | Aug 2012 | A1 |
20120215285 | Tahmasian et al. | Aug 2012 | A1 |
20120232565 | Kveen et al. | Sep 2012 | A1 |
20120277600 | Greenhut | Nov 2012 | A1 |
20120277606 | Ellingson et al. | Nov 2012 | A1 |
20120283795 | Stancer et al. | Nov 2012 | A1 |
20120283807 | Deterre et al. | Nov 2012 | A1 |
20120290025 | Keimel | Nov 2012 | A1 |
20120296381 | Matos | Nov 2012 | A1 |
20120303082 | Dong et al. | Nov 2012 | A1 |
20120316613 | Keefe et al. | Dec 2012 | A1 |
20130012151 | Hankins | Jan 2013 | A1 |
20130023975 | Locsin | Jan 2013 | A1 |
20130035748 | Bonner et al. | Feb 2013 | A1 |
20130041422 | Jacobson | Feb 2013 | A1 |
20130053908 | Smith et al. | Feb 2013 | A1 |
20130053915 | Holmstrom et al. | Feb 2013 | A1 |
20130053921 | Bonner et al. | Feb 2013 | A1 |
20130060298 | Splett et al. | Mar 2013 | A1 |
20130066169 | Rys et al. | Mar 2013 | A1 |
20130072770 | Rao et al. | Mar 2013 | A1 |
20130079798 | Tran et al. | Mar 2013 | A1 |
20130079861 | Reinert et al. | Mar 2013 | A1 |
20130085350 | Schugt et al. | Apr 2013 | A1 |
20130085403 | Gunderson et al. | Apr 2013 | A1 |
20130085550 | Polefko et al. | Apr 2013 | A1 |
20130096649 | Martin et al. | Apr 2013 | A1 |
20130103047 | Steingisser et al. | Apr 2013 | A1 |
20130103109 | Jacobson | Apr 2013 | A1 |
20130110008 | Bourget et al. | May 2013 | A1 |
20130110127 | Bornzin et al. | May 2013 | A1 |
20130110192 | Tran et al. | May 2013 | A1 |
20130110219 | Bornzin et al. | May 2013 | A1 |
20130116529 | Min et al. | May 2013 | A1 |
20130116738 | Samade et al. | May 2013 | A1 |
20130116740 | Bornzin et al. | May 2013 | A1 |
20130116741 | Bornzin et al. | May 2013 | A1 |
20130123872 | Bornzin et al. | May 2013 | A1 |
20130123875 | Varady et al. | May 2013 | A1 |
20130131591 | Berthiaume et al. | May 2013 | A1 |
20130131693 | Berthiaume et al. | May 2013 | A1 |
20130138006 | Bornzin et al. | May 2013 | A1 |
20130150695 | Biela et al. | Jun 2013 | A1 |
20130196703 | Masoud et al. | Aug 2013 | A1 |
20130197609 | Moore et al. | Aug 2013 | A1 |
20130231710 | Jacobson | Sep 2013 | A1 |
20130238072 | Deterre et al. | Sep 2013 | A1 |
20130238073 | Makdissi et al. | Sep 2013 | A1 |
20130253342 | Griswold et al. | Sep 2013 | A1 |
20130253343 | Waldhauser et al. | Sep 2013 | A1 |
20130253344 | Griswold et al. | Sep 2013 | A1 |
20130253345 | Griswold et al. | Sep 2013 | A1 |
20130253346 | Griswold et al. | Sep 2013 | A1 |
20130253347 | Griswold et al. | Sep 2013 | A1 |
20130261497 | Pertijs et al. | Oct 2013 | A1 |
20130265144 | Banna et al. | Oct 2013 | A1 |
20130268042 | Hastings et al. | Oct 2013 | A1 |
20130274828 | Willis | Oct 2013 | A1 |
20130274847 | Ostroff | Oct 2013 | A1 |
20130282070 | Cowan et al. | Oct 2013 | A1 |
20130282073 | Cowan et al. | Oct 2013 | A1 |
20130303872 | Taff et al. | Nov 2013 | A1 |
20130324825 | Ostroff et al. | Dec 2013 | A1 |
20130325081 | Karst et al. | Dec 2013 | A1 |
20130345770 | Dianaty et al. | Dec 2013 | A1 |
20140012344 | Hastings et al. | Jan 2014 | A1 |
20140018876 | Ostroff | Jan 2014 | A1 |
20140018877 | Demmer et al. | Jan 2014 | A1 |
20140031836 | Ollivier | Jan 2014 | A1 |
20140039570 | Carroll et al. | Feb 2014 | A1 |
20140039591 | Drasler et al. | Feb 2014 | A1 |
20140043146 | Makdissi et al. | Feb 2014 | A1 |
20140046395 | Regnier et al. | Feb 2014 | A1 |
20140046420 | Moore et al. | Feb 2014 | A1 |
20140058240 | Mothilal et al. | Feb 2014 | A1 |
20140058494 | Ostroff et al. | Feb 2014 | A1 |
20140074114 | Khairkhahan et al. | Mar 2014 | A1 |
20140074186 | Faltys et al. | Mar 2014 | A1 |
20140094891 | Pare et al. | Apr 2014 | A1 |
20140100627 | Min | Apr 2014 | A1 |
20140107723 | Hou et al. | Apr 2014 | A1 |
20140121719 | Bonner et al. | May 2014 | A1 |
20140121720 | Bonner et al. | May 2014 | A1 |
20140121722 | Sheldon et al. | May 2014 | A1 |
20140128935 | Kumar et al. | May 2014 | A1 |
20140135865 | Hastings et al. | May 2014 | A1 |
20140142648 | Smith et al. | May 2014 | A1 |
20140148675 | Nordstrom et al. | May 2014 | A1 |
20140148815 | Wenzel et al. | May 2014 | A1 |
20140155950 | Hastings et al. | Jun 2014 | A1 |
20140169162 | Romano et al. | Jun 2014 | A1 |
20140172060 | Bornzin et al. | Jun 2014 | A1 |
20140180306 | Grubac et al. | Jun 2014 | A1 |
20140180366 | Edlund | Jun 2014 | A1 |
20140207149 | Hastings et al. | Jul 2014 | A1 |
20140207210 | Willis et al. | Jul 2014 | A1 |
20140214104 | Greenhut et al. | Jul 2014 | A1 |
20140222098 | Baru et al. | Aug 2014 | A1 |
20140222109 | Moulder | Aug 2014 | A1 |
20140228913 | Molin et al. | Aug 2014 | A1 |
20140236172 | Hastings et al. | Aug 2014 | A1 |
20140243848 | Auricchio et al. | Aug 2014 | A1 |
20140257324 | Fain | Sep 2014 | A1 |
20140276929 | Foster et al. | Sep 2014 | A1 |
20140303704 | Suwito et al. | Oct 2014 | A1 |
20140309706 | Jacobson | Oct 2014 | A1 |
20140379041 | Foster | Dec 2014 | A1 |
20150025612 | Haasl et al. | Jan 2015 | A1 |
20150039041 | Smith et al. | Feb 2015 | A1 |
20150051609 | Schmidt et al. | Feb 2015 | A1 |
20150051610 | Schmidt et al. | Feb 2015 | A1 |
20150051611 | Schmidt et al. | Feb 2015 | A1 |
20150051612 | Schmidt et al. | Feb 2015 | A1 |
20150051613 | Schmidt et al. | Feb 2015 | A1 |
20150051614 | Schmidt et al. | Feb 2015 | A1 |
20150051615 | Schmidt et al. | Feb 2015 | A1 |
20150051616 | Haasl et al. | Feb 2015 | A1 |
20150051682 | Schmidt et al. | Feb 2015 | A1 |
20150057520 | Foster et al. | Feb 2015 | A1 |
20150057558 | Stahmann et al. | Feb 2015 | A1 |
20150057721 | Stahmann et al. | Feb 2015 | A1 |
20150088155 | Stahmann et al. | Mar 2015 | A1 |
20150105836 | Bonner et al. | Apr 2015 | A1 |
20150173655 | Demmer et al. | Jun 2015 | A1 |
20150190638 | Smith et al. | Jul 2015 | A1 |
20150196756 | Stahmann et al. | Jul 2015 | A1 |
20150196757 | Stahmann et al. | Jul 2015 | A1 |
20150196758 | Stahmann et al. | Jul 2015 | A1 |
20150196769 | Stahmann et al. | Jul 2015 | A1 |
20150217119 | Nikolski et al. | Aug 2015 | A1 |
20150221898 | Chi et al. | Aug 2015 | A1 |
20150224315 | Stahmann | Aug 2015 | A1 |
20150224320 | Stahmann | Aug 2015 | A1 |
20150258345 | Smith et al. | Sep 2015 | A1 |
20150290468 | Zhang | Oct 2015 | A1 |
20150297905 | Greenhut et al. | Oct 2015 | A1 |
20150297907 | Zhang | Oct 2015 | A1 |
20150305637 | Greenhut et al. | Oct 2015 | A1 |
20150305638 | Zhang | Oct 2015 | A1 |
20150305639 | Greenhut et al. | Oct 2015 | A1 |
20150305640 | Reinke et al. | Oct 2015 | A1 |
20150305641 | Stadler et al. | Oct 2015 | A1 |
20150305642 | Reinke et al. | Oct 2015 | A1 |
20150306374 | Seifert et al. | Oct 2015 | A1 |
20150306375 | Marshall et al. | Oct 2015 | A1 |
20150306406 | Crutchfield et al. | Oct 2015 | A1 |
20150306407 | Crutchfield et al. | Oct 2015 | A1 |
20150306408 | Greenhut et al. | Oct 2015 | A1 |
20150321016 | O'Brien et al. | Nov 2015 | A1 |
20150328459 | Chin et al. | Nov 2015 | A1 |
20160015322 | Anderson et al. | Jan 2016 | A1 |
20160023000 | Cho et al. | Jan 2016 | A1 |
20160030757 | Jacobson | Feb 2016 | A1 |
20160033177 | Barot et al. | Feb 2016 | A1 |
20160051823 | Maile et al. | Feb 2016 | A1 |
20160121127 | Klimovitch et al. | May 2016 | A1 |
20160121128 | Fishler et al. | May 2016 | A1 |
20160121129 | Persson et al. | May 2016 | A1 |
20160213919 | Suwito et al. | Jul 2016 | A1 |
20160213937 | Reinke et al. | Jul 2016 | A1 |
20160213939 | Carney et al. | Jul 2016 | A1 |
20160228026 | Jackson | Aug 2016 | A1 |
20160256694 | Shuros et al. | Sep 2016 | A1 |
20170056665 | Kane et al. | Mar 2017 | A1 |
Number | Date | Country |
---|---|---|
2008279789 | Oct 2011 | AU |
2008329620 | May 2014 | AU |
2014203793 | Jul 2014 | AU |
1003904 | Jan 1977 | CA |
202933393 | May 2013 | CN |
0362611 | Apr 1990 | EP |
503823 | Sep 1992 | EP |
1702648 | Sep 2006 | EP |
1904166 | Jun 2011 | EP |
2433675 | Jan 2013 | EP |
2441491 | Jan 2013 | EP |
2452721 | Nov 2013 | EP |
2662113 | Nov 2013 | EP |
1948296 | Jan 2014 | EP |
2471452 | Dec 2014 | EP |
2760541 | May 2016 | EP |
2833966 | May 2016 | EP |
2000051373 | Feb 2000 | JP |
2002502640 | Jan 2002 | JP |
2004512105 | Apr 2004 | JP |
2005508208 | Mar 2005 | JP |
2005245215 | Sep 2005 | JP |
2008540040 | Nov 2008 | JP |
5199867 | Feb 2013 | JP |
9500202 | Jan 1995 | WO |
9636134 | Nov 1996 | WO |
9826840 | Jun 1998 | WO |
9939767 | Aug 1999 | WO |
0234330 | Jan 2003 | WO |
02098282 | May 2003 | WO |
2005000206 | Jan 2005 | WO |
2005042089 | May 2005 | WO |
2006086435 | Aug 2006 | WO |
2006113659 | Oct 2006 | WO |
2006124833 | Nov 2006 | WO |
2007075974 | Jul 2007 | WO |
2009006531 | Jan 2009 | WO |
2012054102 | Apr 2012 | WO |
2013080038 | Jun 2013 | WO |
2013098644 | Jul 2013 | WO |
2013184787 | Dec 2013 | WO |
Entry |
---|
US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn) |
“Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter,” Nanostim Leadless Pacemakers, pp. 1-28, 2013. |
Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th ntemational Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003. |
International Search Report and Written Opinion dated Feb. 6, 2017 for International Application No. PCT/US2016/048353. |
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, dated Dec. 9, 2016. |
Wegmüller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated Jan. 29, 2016, 15 pages. |
Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering,vol. 60(8): 2067-2079, 2013. |
Spickler et al., “Totally Self-Contained Intracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(3&4): 324-331, 1970. |
Number | Date | Country | |
---|---|---|---|
20180207426 A1 | Jul 2018 | US |
Number | Date | Country | |
---|---|---|---|
62210882 | Aug 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15243524 | Aug 2016 | US |
Child | 15935806 | US |